



STIC Search Report

Biotech-Chem Library

STIC Database Tracking Number: 168958

TO: Shobha Kantamneni
Location: rem/4A10/4B18
Art Unit: 1617
Monday, October 24, 2005
Case Serial Number: 10/675927

From: Toby Port
Location: Biotech-Chem Library
REM-1A59
Phone: 571-272-2523

toby.port@uspto.gov

Search Notes

Examiner Kantamneni,

See attached results.

If you have any questions about this search feel free to contact me at any time.

Thank you for using STIC search services!

Toby Port
X22523

=> file reg; d stat que 19
 FILE 'REGISTRY' ENTERED AT 11:30:33 ON 24 OCT 2005
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
 provided by InfoChem.

STRUCTURE FILE UPDATES: 23 OCT 2005 HIGHEST RN 865836-54-0
 DICTIONARY FILE UPDATES: 23 OCT 2005 HIGHEST RN 865836-54-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

Please note that search-term pricing does apply when
 conducting SmartSELECT searches.

 *
 * The CA roles and document type information have been removed from *
 * the IDE default display format and the ED field has been added, *
 * effective March 20, 2005. A new display format, IDERL, is now *
 * available and contains the CA role and document type information. *
 *

Structure search iteration limits have been increased. See HELP SLIMITS
 for details.


REGISTRY includes numerically searchable data for experimental and
 predicted properties as well as tags indicating availability of
 experimental property data in the original document. For information
 on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

L6

STR

G3 @17 Ak @27



O---Hy-- G2
 @11 12 13

NH-- Ak
 @32 33

*Full file search run on
 this structure*

S---Hy-- G2
 @28 29 30

34
 Ak
 N---Ak
 @35 36

37
 O
 C---G4
 @38 39

NH^C
 @40 41

42
 C
 N---C
 @43 44

N @45

VAR G2=HY/38

VAR G3=11/28
VAR G4=OH/45/NH2/40/43
VAR G6=H/OH/32/35/27
VAR G7=27/H
VPA 17-8/9 U
NODE ATTRIBUTES:
NSPEC IS RC AT 15
NSPEC IS RC AT 41
NSPEC IS RC AT 42
NSPEC IS RC AT 44
NSPEC IS R AT 45
CONNECT IS E1 RC AT 27
CONNECT IS E1 RC AT 33
CONNECT IS E1 RC AT 34
CONNECT IS E1 RC AT 36
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 35

STEREO ATTRIBUTES: NONE
L9 1179 SEA FILE=REGISTRY SSS FUL L6

100.0% PROCESSED 32662 ITERATIONS 1179 ANSWERS
SEARCH TIME: 00.00.01

=> file caplus; d que nos l10
FILE 'CAPLUS' ENTERED AT 11:30:52 ON 24 OCT 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 24 Oct 2005 VOL 143 ISS 18
FILE LAST UPDATED: 23 Oct 2005 (20051023/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

L6 STR
L9 1179 SEA FILE=REGISTRY SSS FUL L6
L10 7 SEA FILE=CAPLUS ABB=ON PLU=ON L9

=> d ibib abs hitstr l10 1-7

L10 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:857399 CAPLUS

DOCUMENT NUMBER: 141:343478

TITLE: Use of small molecule compounds for immunopotential

INVENTOR(S): Valiante, Nicholas

PATENT ASSIGNEE(S): Chiron Corporation, USA

SOURCE: PCT Int. Appl., 146 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent


LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|-------------------|----------|-----------------|------------|
| WO 2004087153 | A2 | 20041014 | WO 2004-US10331 | 20040329 |
| WO 2004087153 | A3 | 20050317 | | |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| US 2005136065 | A1 | 20050623 | US 2004-814480 | 20040329 |
| PRIORITY APPLN. INFO.: | | | US 2003-458888P | P 20030328 |
| OTHER SOURCE(S): | MARPAT 141:343478 | | | |

GI



I


AB The invention provides immunostimulatory compns. comprising a small mol. immunopotentiator (SMIP) compound and methods of administration thereof. Also provided are methods of administering a SMIP compound in an effective amount to enhance the immune response of a subject to an antigen. Further provided are compns. and methods of administering SMIP compds. alone or in combination with another agent for the treatment of cancer, infectious diseases and/or allergies/asthma. Preparation of selected compds., e.g. I, is included.

IT 611213-07-1 611214-93-8 611215-16-8
611216-17-2 611223-31-5 774196-96-2
774196-97-3

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(small mol. compds. for immunopotentialiation)


RN 611213-07-1 CAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[2-[[2-(1-methylethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)




RN 611214-93-8 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-([1,1'-bicyclohexyl]-2-ylamino)-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611215-16-8 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(2-benzoylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611216-17-2 CAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[6-(1-pyrrolidinyl)-3-pyridinyl]amino]-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)




RN 611223-31-5 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(2-methoxyphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(3-methoxypropyl)- (9CI) (CA INDEX NAME)




RN 774196-96-2 CAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[3-[(trimethylsilyl)ethynyl]phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)



RN 774196-97-3 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-chlorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-2-thiazolyl- (9CI) (CA INDEX NAME)




IT 611212-56-7P 611213-70-8P

RL: SPN (Synthetic preparation); PREP (Preparation)
(small mol. compds. for immunopotential)


RN 611212-56-7 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-chloro-3-(trifluoromethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611213-70-8 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



L10 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:817883 CAPLUS

DOCUMENT NUMBER: 141:332190

TITLE: Preparation of fused azoles such as 2,5-disubstituted benzimidazoles, benzoxazoles and benzothiazoles as kinase inhibitors

INVENTOR(S): Dipietro, Lucian V.; Harmange, Jean-Christophe; Askew, Benny C., Jr.; Elbaum, Daniel; Germain, Julie; Habgood, Gregory J.; Kim, Joseph L.; Patel, Vinod F.; Potashman, Michele; Van der Plas, Simon

PATENT ASSIGNEE(S): Amgen Inc., USA

SOURCE: PCT Int. Appl., 289 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English



FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-----------------|------------|
| WO 2004085425 | A1 | 20041007 | WO 2004-US8809 | 20040322 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| US 2004209892 | A1 | 20041021 | US 2004-804915 | 20040319 |
| PRIORITY APPLN. INFO.: | | | US 2003-456691P | P 20030321 |

OTHER SOURCE(S) :
GI

MARPAT 141:332190



AB Title compds. I [W, X, Y1 and Y2 independently = O, S(O)_n and NR₃; ring A optionally contains a N atom at a non-fused, non-substituted ring position; n = 0-2; R = (un)substituted-aryl, -heterocyclyl, -fused heterocyclyl, etc.; R1 = (un)substituted-aryl, -arylalkyl, -heterocyclyl, etc.; R2 = H, halo, alkoxy, etc.; R3 = H or alkyl] are prepared and disclosed as having kinase inhibitory activity, such as VEGFR/KDR inhibitory activity. Thus, e.g., II was prepared by cyclocondensation of 4-(pyridin-4-yloxy)benzene-1,2-diamine with 1-chloro-4-isothiocyanato-2-trifluoromethylbenzene. In human umbilical vein endothelial cell proliferation assay, selected I inhibited VEGF-stimulated proliferation at a level below 100 nM. Accordingly, I would be useful in the prevention and treatment of angiogenesis related disorders, ophthalmol. conditions, proliferative diseases, inflammatory diseases, and other pathol. conditions as described in the specification.


IT 611212-56-7P 769960-01-2P 769960-02-3P
769960-03-4P 769960-04-5P 769960-05-6P
769960-06-7P 769960-07-8P 769960-08-9P
769960-09-0P 769960-10-3P 769960-11-4P
769960-12-5P 769960-13-6P 769960-14-7P
769960-15-8P 769960-16-9P 769960-19-2P
769960-20-5P 769960-82-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of benzimidazole, benzoxazole and benzothiazole derivs. as kinase inhibitors)


RN 611212-56-7 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-chloro-3-(trifluoromethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 769960-01-2 CAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[2-[[4-(pentafluoroethyl)-3-[2-(1-pyrrolidinyl)ethoxy]phenyl]amino]-1H-benzimidazol-5-yl]oxy]-(9CI) (CA INDEX NAME)



RN 769960-02-3 CAPLUS


CN 2-Pyridinecarboxamide, N-methyl-4-[[2-[[3-[2-(1-pyrrolidinyl)ethoxy]-5-(trifluoromethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]-(9CI) (CA INDEX NAME)



RN 769960-03-4 CAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[2-[[4-(pentafluoroethyl)-3-[(2R)-2-pyrrolidinylmethoxy]phenyl]amino]-1H-benzimidazol-5-yl]oxy]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 769960-04-5 CAPLUS


CN 2-Pyridinecarboxamide, N-methyl-4-[[2-[[3-[(2R)-1-methyl-2-pyrrolidinyl]methoxy]-4-(pentafluoroethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 769960-05-6 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[3-[2-(dimethylamino)ethyl]-4-methoxyphenyl]amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 769960-06-7 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[3-(difluoromethoxy)-4-[4-(1-methylethyl)-1-piperazinyl]phenyl]amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 769960-07-8 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[3-[[[(dimethylamino)acetyl]amino]-4-(1,1-dimethylethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]-N-methyl-(9CI) (CA INDEX NAME)




RN 769960-08-9 CAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[2-[[4-[1-methyl-1-(1-methyl-4-piperidiny)ethyl]phenyl]amino]-1H-benzimidazol-5-yl]oxy]-(9CI) (CA INDEX NAME)




RN 769960-09-0 CAPLUS

CN 2(1H)-Isoquinolinecarboxylic acid, 3,4-dihydro-4,4-dimethyl-7-[[5-[[2-[(methylamino)carbonyl]-4-pyridinyl]oxy]-1H-benzimidazol-2-yl]amino]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 769960-10-3 CAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[2-[(1,2,3,4-tetrahydro-4,4-dimethyl-7-isoquinolinyl)amino]-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)




RN 769960-11-4 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-chloro-3-(1-piperazinylmethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 769960-12-5 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[3-[2-(dimethylamino)ethoxy]-4-(trifluoromethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 769960-13-6 CAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[4-chloro-3-[(4-methyl-1-piperazinyl)methyl]phenyl]amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI)
(CA INDEX NAME)



RN 769960-14-7 CAPLUS


CN 2-Pyridinecarboxamide, N-methyl-4-[[2-[[3-[[[(2R)-1-methyl-2-pyrrolidinyl]methoxy]-4-(trifluoromethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 769960-15-8 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-chloro-3-[[4-(1-methylethyl)-1-piperazinyl]methyl]phenyl]amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI)
(CA INDEX NAME)




RN 769960-16-9 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-chloro-3-[[4-(methylsulfonyl)-1-piperazinyl]methyl]phenyl]amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI)
(CA INDEX NAME)




RN 769960-19-2 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-chloro-3-(trifluoromethyl)phenyl]amino]-6-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 769960-20-5 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-chloro-3-[(4-methyl-1-piperazinyl)methyl]phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 769960-82-9 CAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[2-[[3-[(1-methyl-2-pyrrolidinyl)methoxy]-4-(pentafluoroethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)




IT 769961-00-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of benzimidazole, benzoxazole and benzothiazole derivs. as kinase inhibitors)

RN 769961-00-4 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[[2-chloro-5-[[5-[[2-[(methylamino)carbonyl]-4-pyridinyl]oxy]-1H-benzimidazol-2-yl]amino]phenyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

—OBu-t


IT 769961-24-2

RL: RCT (Reactant); RACT (Reactant or reagent)
(starting material; preparation of benzimidazole, benzoxazole and benzothiazole derivs. as kinase inhibitors)

RN 769961-24-2 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 2-[[5-[[5-[[2-[(methylamino)carbonyl]-4-pyridinyl]oxy]-1H-benzimidazol-2-yl]amino]-2-(pentafluoroethyl)phenoxy]methyl]-, 1,1-dimethylethyl ester, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:513393 CAPLUS

DOCUMENT NUMBER: 141:71544

TITLE: Preparation of substituted benzazoles as Raf kinase inhibitors

INVENTOR(S): Amiri, Payman; Fantl, Wendy; Levine, Barry Haskell; Poon, Daniel J.; Ramurthy, Savithri; Renhowe, Paul A.; Subramanian, Sharadha; Sung, Leonard

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 476 pp., Cont.-in-part of U.S. Pat. Appl. 2004 87,626.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:


| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-----------------|----------|
| US 2004122237 | A1 | 20040624 | US 2003-675927 | 20030929 |
| US 2004087626 | A1 | 20040506 | US 2003-405945 | 20030331 |
| WO 2005032548 | A1 | 20050414 | WO 2004-US32161 | 20040929 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |

PRIORITY APPLN. INFO.: US 2002-369066P P 20020329
US 2003-405945 A2 20030331
US 2003-675927 A 20030929

OTHER SOURCE(S): MARPAT 141:71544
GI



I



II

AB The title compds. I [wherein X1, X2 = N, NR4, O, S (with provisos); Y = O, S; A1 = (un)substituted alkyl, (hetero)cycloalkyl(alkyl), (hetero)aryl(alkyl), etc.; A2 = (un)substituted heteroaryl; R1 = O, H; R2 = NR5R6, OH; or CR1R2 = (un)substituted heterocycloalkyl, heteroaryl; R3 = H, halo, alkyl, alkoxy; R4 = H, OH, (di)alkylamino, alkyl; R5, R6 = H, (un)substituted (cyclo)alkyl, alkoxyalkyl, aminoalkyl, amidoalkyl, acyl, heterocyclyl, (hetero)aryl, etc.; or R5 and R6 are taken together to form (un)substituted heterocyclyl or heteroaryl; R7 = alkyl; and pharmaceutically acceptable salts, esters, or prodrugs] were prepared as Raf kinase inhibitors. Examples include synthetic methods and phys. data for 1400 compds., as well as descriptions of two Raf kinase bioassays. For instance, 4-amino-3-nitrophenol and (4-chloropyridin-2-yl)-N-methylcarboxamide were coupled using potassium bis(trimethylsilyl)amide and K2CO3 in DMF to give 4-[(4-amino-3-nitrophenyl)oxy]-N-methylpyridine-2-carboxamide. Pd-catalyzed hydrogenation, followed by cyclization with 4-chloro-3-(trifluoromethyl)benzeneisothiocyanate in the presence of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide•HCl in THF provided the benzimidazole II. One thousand ninety-four compds. inhibited Raf kinase activity with IC50 < 5 μ M in a Raf/Mek filtration assay or a biotinylated Raf screen. Thus, I and their pharmaceutical compns., which may comprise at least one addnl. agent, are useful for the treatment of Raf kinase mediated disorders, such as cancer (no data).

IT 611213-97-9P 611214-71-2P 611214-79-0P


611215-54-4P 611215-68-0P 710351-25-0P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(Raf kinase inhibitor; preparation of substituted benzazoles as Raf kinase inhibitors for treatment of cancer)


RN 611213-97-9 CAPLUS

CN Benzoic acid, 4-[[1-methyl-5-[[2-[(methylamino)carbonyl]-4-pyridinyl]oxy]-1H-benzimidazol-2-yl]amino]- (9CI) (CA INDEX NAME)



RN 710351-75-0 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(3-amino-4-chlorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




IT 611226-42-7

RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of substituted benzazoles as Raf kinase inhibitors for treatment of cancer)

RN 611226-42-7 CAPLUS

CN 2-Pyridinecarboxamide, N-(2-aminoethyl)-4-[[1-methyl-2-[[3-(1-methylethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)



L10 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2003:796477 CAPLUS

DOCUMENT NUMBER: 139:307759

TITLE: Preparation of substituted benzazoles as Raf kinase inhibitors

INVENTOR(S): Renhowe, Paul A.; Ramurthy, Savithri; Amiri, Payman; Levine, Barry Haskell; Poon, Daniel J.; Subramanian, Sharadha; Sung, Leonard; Fantl, Wendy

PATENT ASSIGNEE(S): Chiron Corporation, USA

SOURCE: PCT Int. Appl., 259 pp.

CODEN: PIXXD2



DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-------------------|------------|
| WO 2003082272 | A1 | 20031009 | WO 2003-US10117 | 20030331 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| CA 2480638 | AA | 20031009 | CA 2003-2480638 | 20030331 |
| EP 1499311 | A1 | 20050126 | EP 2003-745683 | 20030331 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK | | | | |
| BR 2003008854 | A | 20050222 | BR 2003-8854 | 20030331 |
| JP 2005529089 | T2 | 20050929 | JP 2003-579810 | 20030331 |
| PRIORITY APPLN. INFO.: | | | US 2002-369066P | P 20020329 |
| | | | WO 2003-US10117 | W 20030331 |
| OTHER SOURCE(S): | | | MARPAT 139:307759 | |
| GI | | | | |



AB The title compds. [I; X1, X2 = N, NR4, O, S (with the provisos); Y = O, S; A1 = (un)substituted alkyl, cycloalkyl, aryl, etc.; A2 = (un)substituted heteroaryl; R1 = O, H, and R2 = NR5R6, OH; or CR1R2 = (un)substituted heterocycloalkyl, heteroaryl; R3 = H, halo, alkyl, alkoxy; R4 = H, OH, (di)alkylamino, alkyl; R5, R6 = H, (un)substituted alkyl, alkoxyalkyl, etc.; or R5 and R6 are taken together to form (un)substituted heterocyclyl or heteroaryl], useful for inhibition of Raf kinase activity in a human or animal subject, were prepared E.g., a 3-step synthesis of the benzimidazole II (starting from 4-amino-3-nitrophenol and (4-chloropyridin-2-yl)-N-

methylcarboxamide), was given. The compds. of examples 1-1094 showed a Raf kinase inhibitory activity at an IC₅₀ of less than 5 μ M. A composition comprising the compound I is claimed. The new compds. compns. may be used either alone or in combination with at least one addnl. agent for the treatment of a Raf kinase mediated disorder, such as cancer.


IT 611213-97-9P 611214-71-2P 611214-79-0P

611215-54-4P 611215-68-0P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of substituted benzazoles as Raf kinase inhibitors)


RN 611213-97-9 CAPLUS

CN Benzoic acid, 4-[[1-methyl-5-[[2-[(methylamino)carbonyl]-4-pyridinyl]oxy]-1H-benzimidazol-2-yl]amino]- (9CI) (CA INDEX NAME)




RN 611214-71-2 CAPLUS

CN Benzoic acid, 3-[[1-methyl-5-[[2-[(methylamino)carbonyl]-4-pyridinyl]oxy]-1H-benzimidazol-2-yl]amino]- (9CI) (CA INDEX NAME)




RN 611214-79-0 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(3-iodophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611215-54-4 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(3-ethynylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611215-68-0 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(2,3-dihydro-1H-indol-6-yl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



IT 611212-56-7P 611212-57-8P 611212-58-9P
 611212-59-0P 611212-60-3P 611212-61-4P
 611212-62-5P 611212-63-6P 611212-64-7P
 611212-65-8P 611212-66-9P 611212-67-0P
 611212-68-1P 611212-69-2P 611212-70-5P
 611212-71-6P 611212-72-7P 611212-73-8P
 611212-74-9P 611212-75-0P 611212-76-1P
 611212-77-2P 611212-78-3P 611212-79-4P
 611212-80-7P 611212-81-8P 611212-82-9P
 611212-83-0P 611212-84-1P 611212-85-2P
 611212-86-3P 611212-87-4P 611212-88-5P
 611212-89-6P 611212-90-9P 611212-91-0P
 611212-92-1P 611212-93-2P 611212-94-3P
 611212-95-4P 611212-96-5P 611212-97-6P
 611212-98-7P 611212-99-8P 611213-00-4P
 611213-01-5P 611213-02-6P 611213-03-7P
 611213-04-8P 611213-05-9P 611213-06-0P
 611213-07-1P 611213-08-2P 611213-09-3P
 611213-10-6P 611213-11-7P 611213-12-8P
 611213-13-9P 611213-14-0P 611213-15-1P
 611213-16-2P 611213-17-3P 611213-18-4P
 611213-19-5P 611213-20-8P 611213-21-9P
 611213-22-0P 611213-23-1P 611213-24-2P
 611213-25-3P 611213-26-4P 611213-27-5P
 611213-28-6P 611213-29-7P 611213-30-0P
 611213-31-1P 611213-32-2P 611213-33-3P
 611213-34-4P 611213-35-5P 611213-36-6P
 611213-37-7P 611213-38-8P 611213-39-9P
 611213-40-2P 611213-41-3P 611213-42-4P
 611213-43-5P 611213-44-6P 611213-45-7P
 611213-46-8P 611213-47-9P 611213-48-0P
 611213-49-1P 611213-50-4P 611213-51-5P
 611213-53-7P 611213-54-8P 611213-55-9P
 611213-56-0P 611213-57-1P 611213-58-2P
 611213-60-6P 611213-70-8P 611213-71-9P
 611213-72-0P 611213-73-1P 611213-74-2P
 611213-75-3P 611213-76-4P 611213-77-5P


611213-78-6P 611213-79-7P 611213-80-0P
 611213-81-1P 611213-82-2P 611213-83-3P
 611213-84-4P 611213-85-5P 611213-86-6P
 611213-87-7P 611213-88-8P 611213-89-9P
 611213-90-2P 611213-91-3P 611213-92-4P
 611213-93-5P 611213-94-6P 611213-95-7P
 611213-96-8P 611213-98-0P 611213-99-1P
 611214-00-7P 611214-01-8P 611214-02-9P
 611214-03-0P 611214-04-1P 611214-05-2P
 611214-06-3P 611214-08-5P 611214-09-6P
 611214-10-9P 611214-11-0P 611214-12-1P
 611214-13-2P 611214-14-3P 611214-15-4P
 611214-16-5P 611214-17-6P 611214-18-7P
 611214-19-8P 611214-20-1P 611214-21-2P
 611214-22-3P 611214-23-4P 611214-24-5P
 611214-25-6P 611214-26-7P 611214-27-8P
 611214-28-9P 611214-29-0P 611214-30-3P
 611214-31-4P 611214-32-5P 611214-33-6P
 611214-34-7P 611214-35-8P 611214-36-9P
 611214-37-0P 611214-38-1P 611214-39-2P
 611214-40-5P 611214-41-6P 611214-42-7P
 611214-43-8P 611214-44-9P 611214-46-1P
 611214-47-2P 611214-48-3P 611214-49-4P
 611214-50-7P 611214-51-8P 611214-52-9P
 611214-53-0P 611214-54-1P 611214-55-2P
 611214-56-3P 611214-57-4P 611214-58-5P
 611214-59-6P 611214-60-9P 611214-61-0P
 611214-62-1P 611214-63-2P 611214-64-3P
 611214-65-4P 611214-66-5P 611214-67-6P
 611214-68-7P 611214-69-8P 611214-70-1P
 611214-72-3P 611214-73-4P 611214-74-5P
 611214-75-6P 611214-76-7P 611214-77-8P
 611214-78-9P 611214-80-3P 611214-82-5P
 611214-83-6P 611214-84-7P 611214-85-8P
 611214-86-9P 611214-87-0P 611214-88-1P
 611214-89-2P 611214-90-5P 611214-91-6P
 611214-92-7P 611214-93-8P 611214-94-9P
 611214-95-0P 611214-96-1P 611214-97-2P
 611214-98-3P 611214-99-4P 611215-00-0P
 611215-01-1P 611215-02-2P 611215-03-3P
 611215-04-4P 611215-05-5P 611215-06-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(preparation of substituted benzazoles as Raf kinase inhibitors)


RN 611212-56-7 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-chloro-3-(trifluoromethyl)phenyl]amino]-
 1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611212-57-8 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(3-chlorophenyl)amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611212-58-9 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromophenyl)amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611212-59-0 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(3-chloro-4-fluorophenyl)amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611212-60-3 CAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[2-(phenylamino)-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)




RN 611212-61-4 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-bromo-2-(trifluoromethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611212-62-5 CAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[2-[(2-methylpropyl)amino]-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)




RN 611212-63-6 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-(dimethylamino)-1-naphthalenyl]amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611212-64-7 CAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[2-[(4-nitrophenyl)amino]-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)




RN 611212-65-8 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-(benzoylamino)-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611212-66-9 CAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[2-[(phenylmethyl)amino]-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)




RN 611212-67-0 CAPLUS

CN Benzoic acid, 4-[[5-[[2-[(methylamino)carbonyl]-4-pyridinyl]oxy]-1H-benzimidazol-2-yl]amino]-, methyl ester (9CI) (CA INDEX NAME)




RN 611212-68-1 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-chlorophenyl)amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611212-69-2 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(2-ethoxyphenyl)amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611212-70-5 CAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[2-[[2-(4-morpholinyl)ethyl]amino]-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)




RN 611212-71-6 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-iodophenyl)amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611212-72-7 CAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[2-[[4-(trifluoromethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)




RN 611212-73-8 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(2-(4-(trifluoromethyl)phenyl)amino)-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611212-74-9 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromo-3-methylphenyl)amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611212-75-0 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-acetylphenyl)amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611212-76-1 CAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[2-[(2,4,6-trimethylphenyl)amino]-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)




RN 611212-77-2 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-(1,1-dimethylethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611212-78-3 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(2-bromophenyl)amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611212-79-4 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(3-bromophenyl)amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611212-80-7 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(2-chlorophenyl)amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611212-81-8 CAPLUS


CN 2-Thiophenecarboxylic acid, 3-[[5-[[2-[(methylamino)carbonyl]-4-pyridinyl]oxy]-1H-benzimidazol-2-yl]amino]-, methyl ester (9CI) (CA INDEX NAME)



RN 611212-82-9 CAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromophenyl)amino]-1H-benzimidazol-5-yl]oxy]-N-[(3R,5R)-5-(methoxymethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 611212-83-0 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(2,5-difluorophenyl)amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611212-84-1 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(2,4-difluorophenyl)amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611212-85-2 CAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[2-[[2-(trifluoromethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)




RN 611212-86-3 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(3,4-dichlorophenyl)amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611212-87-4 CAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[2-[[2-(methylthio)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)




RN 611212-88-5 CAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[2-[[4-(methylthio)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)




RN 611212-89-6 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(2-methoxyphenyl)amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611212-90-9 CAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(2-fluorophenyl)amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611212-91-0 CAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[4-(aminosulfonyl)phenyl]amino]-1H-

benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611212-92-1 CAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[2-[[2-(trifluoromethoxy)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)




RN 611212-93-2 CAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[2-[[2-fluoro-5-(trifluoromethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)




RN 611212-94-3 CAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[2-[[2-fluoro-5-(trifluoromethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)




RN 611212-95-4 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(2,4-dichlorophenyl)amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611212-96-5 CAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[2-[[3-(trifluoromethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)




RN 611212-97-6 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(3-methoxyphenyl)amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611212-98-7 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(1,1'-biphenyl)-2-ylamino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611212-99-8 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[2-chloro-5-(trifluoromethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611213-00-4 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(2,5-dimethoxyphenyl)amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611213-01-5 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(3,5-difluorophenyl)amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611213-02-6 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(2-ethylphenyl)amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611213-03-7 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(2,6-difluorophenyl)amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611213-04-8 CAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[3,5-bis(trifluoromethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611213-05-9 CAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(2-methoxy-5-methylphenyl)amino]-1H-

benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611213-06-0 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-6-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611213-07-1 CAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[2-[[2-(1-methylethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)




RN 611213-08-2 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(2-methoxy-4-nitrophenyl)amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611213-09-3 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(3,5-dimethoxyphenyl)amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611213-10-6 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(5-chloro-2,4-dimethoxyphenyl)amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611213-11-7 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-ethylphenyl)amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611213-12-8 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-cyclohexylphenyl)amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611213-13-9 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(3,4-difluorophenyl)amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611213-14-0 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(3,4-dimethylphenyl)amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611213-15-1 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromo-3-chlorophenyl)amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611213-16-2 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-butylphenyl)amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611213-17-3 CAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[2-[[4-(1-methylethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)



RN 611213-18-4 CAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(2,6-dichlorophenyl)amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611213-19-5 CAPLUS


CN 2-Pyridinecarboxamide, N-methyl-4-[[2-[(4-phenoxyphenyl)amino]-1H-

benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)




RN 611213-20-8 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(3,5-dimethylphenyl)amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611213-21-9 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-(diethylamino)phenyl]amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611213-22-0 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-chloro-2-methylphenyl)amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611213-23-1 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromo-2-chlorophenyl)amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611213-24-2 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[2-bromo-4-(1-methylethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611213-25-3 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(2-chloro-4-methylphenyl)amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611213-26-4 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(2-bromo-4-methylphenyl)amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611213-27-5 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[2-chloro-4-(trifluoromethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611213-28-6 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-chloro-2-fluorophenyl)amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611213-29-7 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(2,3-dihydro-1H-inden-5-yl)amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611213-30-0 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(2,5-dimethylphenyl)amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611213-31-1 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-fluoro-2-methylphenyl)amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611213-32-2 CAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[2-[(2,3,5-trifluorophenyl)amino]-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)




RN 611213-33-3 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(2-chloro-5-fluorophenyl)amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611213-34-4 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromo-3-fluorophenyl)amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611213-35-5 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[3-(1,1-dimethylethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611213-36-6 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(2,4-dibromophenyl)amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611213-37-7 CAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(2,5-dichlorophenyl)amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611213-38-8 CAPLUS


CN 2-Pyridinecarboxamide, N-methyl-4-[[2-[[4-(trifluoromethoxy)phenyl]amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)

1H-benzimidazol-5-yl]oxy] - (9CI) (CA INDEX NAME)




RN 611213-39-9 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(1,3-benzodioxol-5-ylamino)-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611213-40-2 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(3-chloro-4-methylphenyl)amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611213-41-3 CAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(4-chloro-3-methylphenyl)amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611213-42-4 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[[3-chloro-4-(trifluoromethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611213-43-5 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[[4-fluoro-3-(trifluoromethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611213-44-6 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[[4-chloro-3-fluorophenyl]amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611213-45-7 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[[4-bromo-2-(trifluoromethoxy)phenyl]amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611213-46-8 CAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[2-[[3-(methythio)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)




RN 611213-47-9 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-methoxyphenyl)amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611213-48-0 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(3-ethylphenyl)amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611213-49-1 CAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[2-[[4-[(trifluoromethyl)thio]phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)




RN 611213-50-4 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-fluorophenyl)amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611213-51-5 CAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[2-[[3-[(trifluoromethylthio)thio]phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)




RN 611213-53-7 CAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[2-[[4-methyl-3-(trifluoromethylthio)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)




RN 611213-54-8 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromo-2-fluorophenyl)amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611213-55-9 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(5-chloro-2-methoxyphenyl)amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611213-56-0 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-methoxy[1,1'-biphenyl]-3-yl)amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611213-57-1 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(3-fluorophenyl)amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611213-58-2 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[3-bromo-4-(trifluoromethoxy)phenyl]amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611213-60-6 CAPLUS

CN 2-Pyridinecarboxamide, N-(4-bromophenyl)-4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)




RN 611213-70-8 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611213-71-9 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-chloro-3-(trifluoromethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611213-72-0 CAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[4-(trifluoromethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy] - (9CI) (CA INDEX NAME)




RN 611213-73-1 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-chlorophenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611213-74-2 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-iodophenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611213-75-3 CAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[4-methylphenyl]amino]-1H-benzimidazol-5-yl]oxy] - (9CI) (CA INDEX NAME)




RN 611213-76-4 CAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[4-phenoxyphenyl]amino]-1H-benzimidazol-5-yl]oxy] - (9CI) (CA INDEX NAME)




RN 611213-77-5 CAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[4-(trifluoromethoxy)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)




RN 611213-78-6 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-butylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611213-79-7 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromo-3-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611213-80-0 CAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[(4-nitrophenyl)amino]-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)




RN 611213-81-1 CAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[4-(1-methylethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)




RN 611213-82-2 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(3,4-dichlorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611213-83-3 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromo-3-methylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611213-84-4 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(3,4-dimethylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611213-85-5 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(3-chloro-4-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611213-86-6 CAPLUS

CN Benzoic acid, 4-[[1-methyl-5-[[2-[(methylamino)carbonyl]-4-pyridinyl]oxy]-1H-benzimidazol-2-yl]amino]-, methyl ester (9CI) (CA INDEX NAME)




RN 611213-87-7 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromo-3-chlorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611213-88-8 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(3-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611213-89-9 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-acetylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611213-90-2 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-(1,1-dimethylethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611213-91-3 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-methoxyphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611213-92-4 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-cyclohexylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611213-93-5 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(3,4-difluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611213-94-6 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-methoxy-2-methylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611213-95-7 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(3-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611213-96-8 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(3-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611213-98-0 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-(benzoylamino)-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611213-99-1 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[2-chloro-5-(trifluoromethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611214-00-7 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(2,5-dimethoxyphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611214-01-8 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(2,4-difluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611214-02-9 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(3,5-difluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611214-03-0 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-ethylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611214-04-1 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(2-methoxy-4-nitrophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611214-05-2 CAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[2-(trifluoromethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)




RN 611214-06-3 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(3-methoxyphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611214-08-5 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(2-ethylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611214-09-6 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(2,5-difluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611214-10-9 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(2,6-dichlorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611214-11-0 CAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[2-(methylthio)phenyl]amino]-1H-benzimidazol-5-yl]oxy] - (9CI) (CA INDEX NAME)




RN 611214-12-1 CAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[4-(methylthio)phenyl]amino]-1H-benzimidazol-5-yl]oxy] - (9CI) (CA INDEX NAME)




RN 611214-13-2 CAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[2-(trifluoromethoxy)phenyl]amino]-1H-benzimidazol-5-yl]oxy] - (9CI) (CA INDEX NAME)




RN 611214-14-3 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[2-fluoro-5-(trifluoromethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611214-15-4 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-cyanophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611214-16-5 CAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[3-(trifluoromethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)




RN 611214-17-6 CAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[2-(1-methylethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)




RN 611214-18-7 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(5-chloro-2,4-dimethoxyphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611214-19-8 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-([1,1'-biphenyl]-2-ylamino)-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611214-20-1 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-((3-ethylphenyl)amino)-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611214-21-2 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-((4-bromophenyl)amino)-1-ethyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611214-22-3 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-((4-bromophenyl)amino)-1-ethyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611214-23-4 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-aminophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611214-24-5 CAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[4-(methylamino)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)




RN 611214-25-6 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-(dimethylamino)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611214-26-7 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(2-methoxy-5-methylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611214-27-8 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(3,5-dimethoxyphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611214-28-9 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(2,6-difluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611214-29-0 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(3,5-bis(trifluoromethyl)phenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611214-30-3 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-methoxy[1,1'-biphenyl]-3-yl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611214-31-4 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(2,4-dimethylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611214-32-5 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(2-chloro-5-nitrophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611214-33-6 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-methoxy-2-nitrophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611214-34-7 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-chloro-2-(trifluoromethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611214-35-8 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(3-chloro-2-methylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611214-36-9 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611214-37-0 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(2,3-dimethylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611214-38-1 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(5-chloro-2-methoxyphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611214-39-2 CAPLUS

| | | | |
|----|---|-------|-----------------|
| CN | 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[4-(5-oxazolyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- | (9CI) | (CA INDEX NAME) |
|----|---|-------|-----------------|




RN 611214-40-5 CAPLUS

2-Pyridinecarboxamide, 4-[[2-[(2-ethoxyphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611214-41-6 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(2-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611214-42-7 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-(cyclohexylamino)-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611214-43-8 CAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[(3-nitrophenyl)amino]-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)




RN 611214-44-9 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(3-cyanophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611214-46-1 CAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[4-(1H-pyrazol-1-yl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)




RN 611214-47-2 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(2-chlorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611214-48-3 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-(cyclopropylamino)-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611214-49-4 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-ethoxyphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611214-50-7 CAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[3-(phenylmethoxy)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)




RN 611214-51-8 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(2,3-dihydro-1H-inden-5-yl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611214-52-9 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(2-ethyl-6-methylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611214-53-0 CAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[4-(4-nitrophenoxy)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)




RN 611214-54-1 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(cyclohexylmethyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611214-55-2 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-bromo-3-(trifluoromethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611214-56-3 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-(aminoiminomethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611214-57-4 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(1-acetyl-2,3-dihydro-1H-indol-6-yl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611214-58-5 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-fluoro-3-(trifluoromethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611214-59-6 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-(cycloheptylamino)-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611214-60-9 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(3-acetylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611214-61-0 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-(bicyclo[2.2.1]hept-2-ylamino)-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611214-62-1 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[2-methoxy-5-(trifluoromethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611214-63-2 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-(1-hydroxyethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611214-64-3 CAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[2-(1-pyrrolidinyl)ethyl]amino]-1H-benzimidazol-5-yl]oxy] - (9CI) (CA INDEX NAME)




RN 611214-65-4 CAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-5-yl]oxy] - (9CI) (CA INDEX NAME)



RN 611214-66-5 CAPLUS


CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[3-(2-oxo-1-pyrrolidinyl)propyl]amino]-1H-benzimidazol-5-yl]oxy] - (9CI) (CA INDEX NAME)



RN 611214-67-6 CAPLUS


CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[2-(1-methyl-2-pyrrolidinyl)ethyl]amino]-1H-benzimidazol-5-yl]oxy] - (9CI) (CA INDEX NAME)

NAME)




RN 611214-68-7 CAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[2-(4-morpholinyl)ethyl]amino]-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)




RN 611214-69-8 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(2,4-dimethoxyphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611214-70-1 CAPLUS

CN Benzoic acid, 3-[[1-methyl-5-[[2-[(methylamino)carbonyl]-4-pyridinyl]oxy]-1H-benzimidazol-2-yl]amino]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 611214-72-3 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(3,5-dimethyl-4-isoxazolyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611214-73-4 CAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[(5-methyl-3-phenyl-4-isoxazolyl)amino]-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)




RN 611214-74-5 CAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[2-(1,2,3,6-tetrahydro-1-methyl-4-pyridinyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)



RN 611214-75-6 CAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(4-chloro-1H-indazol-3-yl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 611214-76-7 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[[(4-methoxyphenyl)methyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611214-77-8 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(2,3-difluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611214-78-9 CAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[2-(4-morpholinyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)




RN 611214-80-3 CAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[(3,4,5-trimethoxyphenyl)amino]-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)




RN 611214-82-5 CAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[(2-thienylmethyl)amino]-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)



RN 611214-83-6 CAPLUS


CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[5-(2-thienyl)-1H-pyrazol-3-yl]amino]-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 611214-84-7 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(1,3-benzodioxol-5-yl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611214-85-8 CAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(2-iodophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611214-86-9 CAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(2,6-diethylphenyl)amino]-1-methyl-1H-

benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611214-87-0 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[3-(1-hydroxyethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611214-88-1 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-(1H-imidazol-1-yl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611214-89-2 CAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[(2-phenoxyphenyl)amino]-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)




RN 611214-90-5 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(3,4-dimethoxyphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611214-91-6 CAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[2-(4-morpholinyl)-5-(trifluoromethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)




RN 611214-92-7 CAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[(tricyclo[3.3.1.1.3,7]dec-1-ylmethyl)amino]-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)




RN 611214-93-8 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(1,1'-bicyclohexyl)-2-ylamino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611214-94-9 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[[(6,6-dimethylbicyclo[3.1.1]hept-2-yl)methyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611214-95-0 CAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-(tricyclo[3.3.1.1.3,7]dec-1-ylamino)-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)




RN 611214-96-1 CAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[(3-methylphenyl)amino]-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)




RN 611214-97-2 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[[5-fluoro-2-(1H-imidazol-1-yl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611214-98-3 CAPLUS


CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[(5-phenyl-1H-pyrazol-3-yl)amino]-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 611214-99-4 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-[(4-ethyl-1-piperazinyl)methyl]phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611215-00-0 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(2,3-dihydro-1,3-dioxo-1H-isoindol-5-yl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611215-01-1 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(2,3-dihydro-3-oxo-1H-isoindol-5-yl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611215-02-2 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromophenyl)methylamino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611215-03-3 CAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-(2-naphthalenylamino)-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)




RN 611215-04-4 CAPLUS

CN Carbamic acid, [1-methyl-5-[[2-[(methylamino)carbonyl]-4-pyridinyl]oxy]-1H-benzimidazol-2-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 611215-05-5 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[3-(1H-imidazol-1-yl)propyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611215-06-6 CAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[(2-methylphenyl)amino]-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)



IT 611215-07-7P 611215-08-8P 611215-09-9P
611215-10-2P 611215-11-3P 611215-12-4P
611215-13-5P 611215-14-6P 611215-15-7P
611215-16-8P 611215-17-9P 611215-18-0P
611215-21-5P 611215-22-6P 611215-23-7P
611215-24-8P 611215-25-9P 611215-26-0P
611215-27-1P 611215-28-2P 611215-29-3P
611215-30-6P 611215-31-7P 611215-32-8P
611215-33-9P 611215-34-0P 611215-35-1P
611215-36-2P 611215-37-3P 611215-38-4P
611215-39-5P 611215-40-8P 611215-41-9P
611215-42-0P 611215-43-1P 611215-44-2P
611215-45-3P 611215-46-4P 611215-47-5P
611215-48-6P 611215-49-7P 611215-50-0P
611215-51-1P 611215-52-2P 611215-53-3P
611215-56-6P 611215-57-7P 611215-58-8P
611215-60-2P 611215-61-3P 611215-62-4P
611215-63-5P 611215-64-6P 611215-65-7P
611215-66-8P 611215-69-1P 611215-70-4P
611215-71-5P 611215-72-6P 611215-73-7P
611215-74-8P 611215-75-9P 611215-76-0P
611215-77-1P 611215-78-2P 611215-79-3P
611215-80-6P 611215-81-7P 611215-82-8P
611215-83-9P 611215-84-0P 611215-85-1P
611215-86-2P 611215-87-3P 611215-88-4P
611215-89-5P 611215-90-8P 611215-91-9P
611215-92-0P 611215-93-1P 611215-94-2P
611215-95-3P 611215-96-4P 611215-98-6P
611215-99-7P 611216-00-3P 611216-01-4P
611216-02-5P 611216-03-6P 611216-04-7P
611216-05-8P 611216-06-9P 611216-07-0P
611216-08-1P 611216-09-2P 611216-10-5P
611216-11-6P 611216-12-7P 611216-13-8P
611216-14-9P 611216-15-0P 611216-16-1P
611216-17-2P 611216-18-3P 611216-19-4P
611216-20-7P 611216-21-8P 611216-22-9P
611216-23-0P 611216-25-2P 611216-26-3P
611216-27-4P 611216-28-5P 611216-29-6P
611216-30-9P 611216-31-0P 611216-32-1P
611216-33-2P 611216-34-3P 611216-35-4P
611216-36-5P 611216-37-6P 611216-39-8P
611216-40-1P 611216-41-2P 611216-42-3P
611216-43-4P 611216-44-5P 611216-45-6P
611216-46-7P 611216-47-8P 611216-48-9P
611216-49-0P 611216-50-3P 611216-51-4P
611216-52-5P 611216-53-6P 611216-54-7P
611216-55-8P 611216-56-9P 611216-57-0P
611216-58-1P 611216-59-2P 611216-60-5P
611216-61-6P 611216-63-8P 611216-64-9P
611216-65-0P 611216-67-2P 611216-68-3P


611216-69-4P 611216-70-7P 611216-71-8P
 611216-72-9P 611216-73-0P 611216-74-1P
 611216-75-2P 611216-76-3P 611216-77-4P
 611216-78-5P 611216-79-6P 611216-80-9P
 611216-81-0P 611216-82-1P 611216-84-3P
 611216-85-4P 611216-86-5P 611216-87-6P
 611216-88-7P 611216-89-8P 611216-91-2P
 611216-92-3P 611216-93-4P 611216-94-5P
 611216-95-6P 611216-96-7P 611216-97-8P
 611216-98-9P 611216-99-0P 611217-00-6P
 611217-02-8P 611217-03-9P 611217-43-7P
 611217-44-8P 611217-46-0P 611217-47-1P
 611217-48-2P 611217-50-6P 611217-51-7P
 611217-52-8P 611217-54-0P 611217-55-1P
 611217-56-2P 611217-57-3P 611217-58-4P
 611217-59-5P 611217-60-8P 611217-62-0P
 611217-64-2P 611217-66-4P 611217-67-5P
 611217-68-6P 611217-69-7P 611217-70-0P
 611217-71-1P 611217-73-3P 611217-75-5P
 611217-77-7P 611217-79-9P 611217-81-3P
 611217-83-5P 611217-85-7P 611217-88-0P
 611217-90-4P 611217-92-6P 611217-94-8P
 611217-96-0P 611217-98-2P 611218-00-9P
 611218-02-1P 611218-04-3P 611218-07-6P
 611218-09-8P 611218-11-2P 611218-13-4P
 611218-15-6P 611218-17-8P 611218-19-0P
 611218-21-4P 611218-23-6P 611218-25-8P
 611218-27-0P 611218-29-2P 611218-30-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(preparation of substituted benzazoles as Raf kinase inhibitors)


RN 611215-07-7 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(2,6-dimethylphenyl)amino]-1-methyl-1H-
 benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611215-08-8 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[2-(difluoromethoxy)phenyl]amino]-1-methyl-
 1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611215-09-9 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[2-(1,1-dimethylethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611215-10-2 CAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[methyl(4-methylphenyl)amino]-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)




RN 611215-11-3 CAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[3-(methylthio)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)




RN 611215-12-4 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-cyano-2-(trifluoromethoxy)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611215-13-5 CAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[4-[1-(phenylmethyl)amino]ethyl]phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)




RN 611215-14-6 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-(1H-indol-5-ylamino)-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611215-15-7 CAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-(phenylamino)-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)



RN 611215-16-8 CAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(2-benzoylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611215-17-9 CAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[4-bromo-2-(trifluoromethoxy)phenyl]amino]-1-

methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611215-18-0 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(2,4-dibromo-6-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611215-21-5 CAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-(1-isoquinolinylamino)-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 611215-22-6 CAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[2-(1H-pyrazol-1-yl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611215-23-7 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-(1H-indol-6-ylamino)-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611215-24-8 CAPLUS

CN Benzoic acid, 4-[[[1-methyl-5-[[2-[(methylamino)carbonyl]-4-pyridinyl]oxy]-1H-benzimidazol-2-yl]amino]-3-(trifluoromethoxy)-, methyl ester (9CI) (CA INDEX NAME)




RN 611215-25-9 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(2-cyanophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611215-26-0 CAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[2-(phenylthio)phenyl]amino]-1H-benzimidazol-5-yl]oxy]-(9CI) (CA INDEX NAME)




RN 611215-27-1 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[2-(4-chlorophenoxy)-5-(trifluoromethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl-(9CI) (CA INDEX NAME)




RN 611215-28-2 CAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[2-(4-methylphenoxy)-5-(trifluoromethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]-(9CI) (CA INDEX NAME)




RN 611215-29-3 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-chlorophenyl]amino]-1,7-dimethyl-1H-benzimidazol-5-yl]oxy]-N-methyl-(9CI) (CA INDEX NAME)




RN 611215-30-6 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[3-(1,1-dimethylethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611215-31-7 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(3-cyclohexylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611215-32-8 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(2,5-dichlorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611215-33-9 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[2-(2-methoxyphenoxy)-5-(trifluoromethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611215-34-0 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[2-(4-cyanophenoxy)-5-(trifluoromethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611215-35-1 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(2,5-dimethylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611215-36-2 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(5-fluoro-2-methylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611215-37-3 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(2-aminophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611215-38-4 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(2-cyano-5-methylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611215-39-5 CAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[[4-methylphenyl)methyl]amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611215-40-8 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromo-2-methylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611215-41-9 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(5-bromo-2-methylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611215-42-0 CAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[(4-methyl[1,1'-biphenyl]-3-yl)amino]-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)




RN 611215-43-1 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(5-chloro-2-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611215-44-2 CAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(5-cyclohexyl-2-methoxyphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611215-45-3 CAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromo-2-fluorophenyl)amino]-1-methyl-1H-

benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611215-46-4 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(2-amino-4-methylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611215-47-5 CAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[(5,6,7,8-tetrahydro-1-naphthalenyl)amino]-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)




RN 611215-48-6 CAPLUS


CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[4-(methylsulfonyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)




RN 611215-49-7 CAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[3-
[(trifluoromethyl)thio]phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (9CI) (CA
INDEX NAME)


RN 611215-50-0 CAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[4-
[(trifluoromethyl)thio]phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (9CI) (CA
INDEX NAME)

RN 611215-51-1 CAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[1,1'-biphenyl]-3-ylamino]-1-methyl-1H-
benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)

RN 611215-52-2 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[2-chloro-4-methylphenyl]amino]-1-methyl-1H-
benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)


RN 611215-53-3 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[2-bromo-4-(1-methylethyl)phenyl]amino]-1-
methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611215-56-6 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-(7-bromo-4-isopropylphenylamino)-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611215-57-7 CAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[3-(1-methylethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)




RN 611215-58-8 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(3-bromo-4-methylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611215-60-2 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-(9H-fluoren-1-ylamino)-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611215-61-3 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-(9H-fluoren-2-ylamino)-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611215-62-4 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(2,2-difluoro-1,3-benzodioxol-5-yl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611215-63-5 CAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[3-(trifluoromethoxy)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)




RN 611215-64-6 CAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[(1-methylethyl)amino]-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)




RN 611215-65-7 CAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[(2-phenylethyl)amino]-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)



RN 611215-66-8 CAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(3-cycloheptylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611215-69-1 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[2,3-dihydro-1-[1-oxo-3-(4-pyridinyl)propyl]-1H-indol-6-yl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 611215-70-4 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(3-chloro-4-methylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611215-71-5 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-(cyclopentylamino)-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611215-72-6 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-(diethylamino)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611215-73-7 CAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[2-(4-methylphenyl)ethyl]amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611215-74-8 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-bromo-2-(trifluoromethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611215-75-9 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-chloro-2-methylphenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611215-76-0 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[3-(diethylamino)propyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611215-77-1 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromo-2-chlorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611215-78-2 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(3,5-dimethylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611215-79-3 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(2,3-dihydro-1,4-benzodioxin-6-yl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611215-80-6 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(2,3-dihydro-1,4-benzodioxin-6-yl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611215-81-7 CAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[(4-phenoxy-3-pyridinyl)amino]-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)




RN 611215-82-8 CAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[4-(2-pyridinyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)




RN 611215-83-9 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(2-chloro-4-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611215-84-0 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-fluoro-2-methylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611215-85-1 CAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[(2,4,5-trimethylphenyl)amino]-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)




RN 611215-86-2 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[2-chloro-4-(trifluoromethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611215-87-3 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(5-chloro-2-methylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611215-88-4 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-chloro-2-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611215-89-5 CAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[3-(1-methylpropyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)




RN 611215-90-8 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-fluoro-3-methylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611215-91-9 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-chloro-3-methylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611215-92-0 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[3-bromo-4-(trifluoromethoxy)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611215-93-1 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[3-chloro-4-(trifluoromethoxy)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611215-94-2 CAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[4-(3-pyridinyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)




RN 611215-95-3 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[3-chloro-4-(trifluoromethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611215-96-4 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-chloro-3-fluorophenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611215-98-6 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(2-bromo-4-methylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611215-99-7 CAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[(2,3,5-trifluorophenyl)amino]-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)




RN 611216-00-3 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(2,4-dibromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611216-01-4 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(2-chloro-5-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611216-02-5 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[3-chloro-4-[(trifluoromethyl)thio]phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611216-03-6 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(3-chloro-1H-indol-6-yl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611216-04-7 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[3,5-bis(1,1-dimethylethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611216-05-8 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[5-(1,1-dimethylethyl)-2-methoxyphenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611216-06-9 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[2-methoxy-5-(1-methyl-1-phenylethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611216-07-0 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-chloro-2,5-dimethoxyphenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611216-08-1 CAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[4-fluoro-2-(1-methylethoxy)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611216-09-2 CAPLUS


CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[3-(1-methylethoxy)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)

NAME)




RN 611216-10-5 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[3-(3-furanyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611216-11-6 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[4-chloro-2-methoxy-5-methylphenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611216-12-7 CAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[2-methyl-5-(1-methylethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)




RN 611216-13-8 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[2,5-bis(1,1-dimethylethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611216-14-9 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[5-chloro-2-(difluoromethoxy)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611216-15-0 CAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[4-(phenylmethoxy)phenyl]amino]-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)



RN 611216-16-1 CAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[[2-[(cyclohexylmethylamino)methyl]phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 611216-17-2 CAPLUS


CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[[6-(1-pyrrolidinyl)-3-phenyl]amino]-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)

pyridinyl]amino]-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)




RN 611216-18-3 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[[6-(dimethylamino)-3-pyridinyl]amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611216-19-4 CAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[(1-methyl-4-piperidinyl)amino]-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)




RN 611216-20-7 CAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[(4-methylcyclohexyl)amino]-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)




RN 611216-21-8 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(cycloheptylmethyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 611216-22-9 CAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[(3,3,5-trimethylcyclohexyl)amino]-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)



RN 611216-23-0 CAPLUS

CN 2-Pyridinecarboxamide, N-methyl-4-[[1-methyl-2-[(2-methylcyclohexyl)amino]-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)




RN 611216-25-2 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-ethyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 611216-24-1


CMF C22 H20 Br N5 O2



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 611216-26-3 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)




RN 611216-27-4 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 611216-28-5 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)



RN 611216-29-6 CAPLUS


CN Pyrrolidine, 1-[[4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-2-pyridinyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 611216-30-9 CAPLUS


CN 1-Piperidinecarboxylic acid, 3-methoxy-4-[[[4-[[2-[[4-(trifluoromethyl)phenyl]amino]-1H-benzimidazol-5-yl]oxy]-2-pyridinyl]carbonyl]amino]-, ethyl ester, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 611216-31-0 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(dimethylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 611216-32-1 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[(tetrahydro-2-furanyl)methyl]- (9CI) (CA INDEX NAME)




RN 611216-33-2 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 611216-34-3 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(4-piperidinylmethyl)- (9CI) (CA INDEX NAME)




RN 611216-35-4 CAPLUS

CN 3-Pyrrolidinamine, 1-[[4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-2-pyridinyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 611216-36-5 CAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[1-(diphenylmethyl)-3-azetidiny]- (9CI) (CA INDEX NAME)



RN 611216-37-6 CAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(3S)-3-pyrrolidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 611216-39-8 CAPLUS


CN 2-Pyridinecarboxamide, N-(2-aminoethyl)-4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)



RN 611216-40-1 CAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(3R)-3-pyrrolidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 611216-41-2 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(1-piperidinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 611216-42-3 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 611216-43-4 CAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-2-thiazolyl- (9CI) (CA INDEX NAME)



RN 611216-44-5 CAPLUS


CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[(3R,5R)-5-(methoxymethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 611216-45-6 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[(1-ethyl-2-pyrrolidiny)methyl]- (9CI) (CA INDEX NAME)




RN 611216-46-7 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-3-piperidiny]- (9CI) (CA INDEX NAME)




RN 611216-47-8 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[3-(2-oxo-1-pyrrolidiny)propyl]- (9CI) (CA INDEX NAME)




RN 611216-48-9 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[3-(2-oxo-1-pyrrolidiny)propyl]- (9CI) (CA INDEX NAME)




RN 611216-49-0 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)




RN 611216-50-3 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 611216-51-4 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(4-hydroxycyclohexyl)- (9CI) (CA INDEX NAME)




RN 611216-52-5 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)




RN 611216-53-6 CAPLUS

CN 2-Pyridinecarboxamide, N-(1,3-benzodioxol-5-ylmethyl)-4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)




RN 611216-54-7 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 611216-55-8 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[2-(4-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 611216-56-9 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]-N-[3-(4-methyl-1-piperazinyl)propyl]- (9CI) (CA INDEX NAME)



RN 611226-14-3 CAPLUS

CN 2-Pyridinecarboxylic acid, 4-[[2-[(4-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1993:207037 CAPLUS

DOCUMENT NUMBER: 118:207037

TITLE: Determination of methyl 5-hydroxy-2-benzimidazole carbamate in urine by high-performance liquid chromatography with electrochemical detection

AUTHOR(S): Leenheers, L. H.; Engel, R.; Spruit, W. E. T.; Meuling, W. J. A.; Jongen, M. J. M.

CORPORATE SOURCE: Med. Biol. Lab., TNO, Rijswijk, 2280 AA, Neth.

SOURCE: Journal of Chromatography, Biomedical Applications (1993), 613(1), 89-94

CODEN: JCBADL; ISSN: 0378-4347

DOCUMENT TYPE: Journal

LANGUAGE: English

AB A HPLC assay for Me 5-hydroxy-2-benzimidazole carbamate (5-HBC) in urine was developed in order to assess the exposure of workers to the pesticide carbendazim. 5-HBC is measured in urine after hydrolysis, sample clean-up through a strong cation-exchange (SCX) column and extraction with Et acetate. HPLC with electrochem. detection provides selective and sensitive determination of

5-HBC with a detection limit of 5 µg/L. A C18 reversed-phase column was used with 0.06 M ammonium acetate solution (pH 8)-methanol (73:27) as mobile phase. The method was validated with respect to hydrolysis of urine samples, anal. recovery of spiked 5-HBC, stability of 5-HBC conjugates, limit of detection, background and precision. The overall anal. recovery from urine was better than 60%. 5-HBC, excreted in urine as a conjugate, was stable for at least one year when stored at -20°. A background of ca. 5 µg/L was detected in urine from some non-occupationally exposed persons. Between-day coeffs. of variations as calculated from the results of the stability test were 7, 4 and 4% for concns. of 61, 244 and 295 µg/L 5-HBC, resp..

IT 51276-87-0


RL: ANST (Analytical study)

(as carbendazim metabolites in human urine, methylhydroxybenzimidazole anal. by HPLC in relation to)

RN 51276-87-0 CAPLUS

CN β -D-Glucopyranosiduronic acid, 2-[(methoxycarbonyl)amino]-1H-benzimidazol-5-yl (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L10 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1975:107204 CAPLUS

DOCUMENT NUMBER: 82:107204

TITLE: Metabolism of thioureidobenzene fungicides in mice and sheep

AUTHOR(S): Douch, P. G. C.

CORPORATE SOURCE: Wallaceville Anim. Res. Cent., Minist. Agric. Fish., Upper Hutt, N. Z.

SOURCE: Xenobiotica (1974), 4(8), 457-75

CODEN: XENOBH; ISSN: 0049-8254

DOCUMENT TYPE: Journal

LANGUAGE: English

GI For diagram(s), see printed CA Issue.

AB Mouse tissue and sheep liver enzyme preps. metabolized thiophanate (I) [23564-06-9], thiophanate methyl (II) [23564-05-8] and related thioureidobenzene compds. to the benzimidazole derivs. and their 5(6)-hydroxylation products by a mixed function oxidase [9040-60-2] system. The in vitro metabolism to benzimidazole compds. required NADPH [53-57-6], and was inhibited by SKF 525A [62-68-0] and CO [630-08-0]. I and II (0.1 g/kg, orally) were eliminated in vivo partly as Me benzimidazol-2-ylcarbamate [10605-21-7] or Et benzimidazol-2-ylcarbamate [6306-71-4] and their hydroxylated derivs. The hydroxylated metabolites were excreted as glucuronide and sulfate conjugates, and 9-14% of the benzimidazole derivs. were eliminated as conjugates.

IT 51276-87-0 54685-67-5


RL: FORM (Formation, nonpreparative)

(formation of, by thioureidobenzene fungicides, by sheep and mouse liver)

RN 51276-87-0 CAPLUS

CN β -D-Glucopyranosiduronic acid, 2-[(methoxycarbonyl)amino]-1H-benzimidazol-5-yl (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 54685-67-5 CAPLUS

CN β-D-Glucopyranosiduronic acid, 2-[(ethoxycarbonyl)amino]-1H-benzimidazol-5-yl (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L10 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1974:610 CAPLUS

DOCUMENT NUMBER: 80:610

TITLE: Metabolism of benomyl fungicide in mammals

AUTHOR(S): Douch, P. G. C.

CORPORATE SOURCE: Wallaceville Anim. Res. Cent., Minis. Agric. Fish., Upper Hutt, N. Z.

SOURCE: Xenobiotica (1973), 3(6), 367-80

CODEN: XENOBH; ISSN: 0049-8254

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Mice, rabbits, and sheep, administered with benomyl (I) [17804-35-2] produced similar patterns of metabolites to those formed by tissue preps. incubated with I. In all 3 species, 2 metabolites were formed by hydroxylation, and 2 by ester hydrolysis. The hydroxylated metabolites were excreted from all species as the sulfate and glucuronide conjugates. Conjugates with acetic acid were not detected. Approx. 20% of the dose given to each species was eliminated as conjugates of hydroxylated metabolites. Formation of hydroxylated metabolites was inhibited by β-diethylaminoethyl diphenylpropylacetate in vitro. In liver enzyme preps. from all 3 species, 2-aminobenzimidazole [934-32-7] was hydroxylated to give 5-hydroxy-2-aminobenzimidazole.


IT 51276-87-0

RL: FORM (Formation, nonpreparative)
(formation of, as benomyl metabolite)

RN 51276-87-0 CAPLUS

CN β-D-Glucopyranosiduronic acid, 2-[(methoxycarbonyl)amino]-1H-benzimidazol-5-yl (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=> file caold; d que nos l11

FILE 'CAOLD' ENTERED AT 11:33:46 ON 24 OCT 2005

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1907-1966

FILE LAST UPDATED: 01 May 1997 (19970501/UP)

This file contains CAS Registry Numbers for easy and accurate substance identification. Title keywords, authors, patent assignees, and patent information, e.g., patent numbers, are now searchable from 1907-1966. TIFF images of CA abstracts printed between 1907-1966 are available in the PAGE display formats.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file supports REGISTRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

```
L6          STR
L9          1179 SEA FILE=REGISTRY SSS FUL L6
L11         0 SEA FILE=CAOLD ABB=ON  PLU=ON  L9
```

=> file home

FILE 'HOME' ENTERED AT 11:34:04 ON 24 OCT 2005

=> d his full

(FILE 'HOME' ENTERED AT 09:59:06 ON 24 OCT 2005)

FILE 'CAPLUS' ENTERED AT 09:59:13 ON 24 OCT 2005
E US2003-675927/APPS

L1 1 SEA ABB=ON PLU=ON US2003-675927/AP
D IALL
D IALL
D COS

L2 FILE 'ZREGISTRY' ENTERED AT 10:15:44 ON 24 OCT 2005
STR

FILE 'CAPLUS' ENTERED AT 10:48:29 ON 24 OCT 2005
SEL RN L1

FILE 'REGISTRY' ENTERED AT 10:48:46 ON 24 OCT 2005

L3 FILE 'CAPLUS' ENTERED AT 10:48:52 ON 24 OCT 2005
TRA L1 1 RN : 1593 TERMS

L4 FILE 'REGISTRY' ENTERED AT 10:49:00 ON 24 OCT 2005
1593 SEA ABB=ON PLU=ON L3
L5 1294 SEA ABB=ON PLU=ON L4 AND NCNC2-C6/ES

L6 FILE 'ZREGISTRY' ENTERED AT 10:57:52 ON 24 OCT 2005
STR L2

L7 FILE 'REGISTRY' ENTERED AT 11:26:25 ON 24 OCT 2005
50 SEA SSS SAM L6
L8 50 SEA ABB=ON PLU=ON L5 AND L7
L9 1179 SEA SSS FUL L6
SAVE L9 KAN927FU/A TEMP

L10 FILE 'CAPLUS' ENTERED AT 11:28:41 ON 24 OCT 2005
7 SEA ABB=ON PLU=ON L9

L11 FILE 'CAOLD' ENTERED AT 11:28:59 ON 24 OCT 2005
0 SEA ABB=ON PLU=ON L9

FILE 'REGISTRY' ENTERED AT 11:30:33 ON 24 OCT 2005
D STAT QUE L9

FILE 'CAPLUS' ENTERED AT 11:30:52 ON 24 OCT 2005
D QUE NOS L10
D IBIB ABS HITSTR L10 1-7

FILE 'CAOLD' ENTERED AT 11:33:46 ON 24 OCT 2005
D QUE NOS L1
D QUE NOS L11

FILE 'HOME' ENTERED AT 11:34:04 ON 24 OCT 2005

FILE HOME

FILE CAPLUS

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 24 Oct 2005 VOL 143 ISS 18
FILE LAST UPDATED: 23 Oct 2005 (20051023/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

FILE ZREGISTRY

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 23 OCT 2005 HIGHEST RN 865836-54-0
DICTIONARY FILE UPDATES: 23 OCT 2005 HIGHEST RN 865836-54-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.

*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
*

Structure search iteration limits have been increased. See HELP SLIMITS for details.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

FILE REGISTRY

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 23 OCT 2005 HIGHEST RN 865836-54-0
DICTIONARY FILE UPDATES: 23 OCT 2005 HIGHEST RN 865836-54-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.

```
*****
*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
*
*****
```

Structure search iteration limits have been increased. See HELP SLIMITS for details.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

FILE CAOLD

FILE COVERS 1907-1966

FILE LAST UPDATED: 01 May 1997 (19970501/UP)

This file contains CAS Registry Numbers for easy and accurate substance identification. Title keywords, authors, patent assignees, and patent information, e.g., patent numbers, are now searchable from 1907-1966. TIFF images of CA abstracts printed between 1907-1966 are available in the PAGE display formats.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file supports REGISTRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

=>

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1617SXX

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 JUL 20 Powerful new interactive analysis and visualization software,
STN AnaVist, now available
NEWS 4 AUG 11 STN AnaVist workshops to be held in North America
NEWS 5 AUG 30 CA/CAPLUS - Increased access to 19th century research documents
NEWS 6 AUG 30 CASREACT - Enhanced with displayable reaction conditions
NEWS 7 SEP 09 ACD predicted properties enhanced in REGISTRY/ZREGISTRY
NEWS 8 OCT 03 MATHDI removed from STN
NEWS 9 OCT 04 CA/CAPLUS-Canadian Intellectual Property Office (CIPO) added
to core patent offices
NEWS 10 OCT 06 STN AnaVist workshops to be held in North America
NEWS 11 OCT 13 New CAS Information Use Policies Effective October 17, 2005
NEWS 12 OCT 17 STN(R) AnaVist(TM), Version 1.01, allows the export/download
of CAPLUS documents for use in third-party analysis and
visualization tools

NEWS EXPRESS JUNE 13 CURRENT WINDOWS VERSION IS V8.0, CURRENT
MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 13 JUNE 2005

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN Customer
agreement. Please note that this agreement limits use to scientific
research. Use for software development or design or implementation
of commercial gateways or other similar uses is prohibited and may
result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 14:23:09 ON 25 OCT 2005

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

1.26

1.26

FILE 'CAPLUS' ENTERED AT 14:26:41 ON 25 OCT 2005

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 25 Oct 2005 VOL 143 ISS 18
FILE LAST UPDATED: 24 Oct 2005 (20051024/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

```
=> s 611216-25-2/rn
      2 611216-25-2
      0 611216-25-2D
L1    2 611216-25-2/RN
      (611216-25-2 (NOTL) 611216-25-2D )
```


=> d 1-2 ibib abs

L1 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2004:513393 CAPLUS
DOCUMENT NUMBER: 141:71544
TITLE: Preparation of substituted benzazoles as Raf kinase inhibitors
INVENTOR(S): Amiri, Payman; Fantl, Wendy; Levine, Barry Haskell; Poon, Daniel J.; Ramurthy, Savithri; Renhowe, Paul A.; Subramanian, Sharadha; Sung, Leonard
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 476 pp., Cont.-in-part of U.S. Pat. Appl. 2004 87,626.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:


| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---------------|--|----------|-----------------|----------|
| US 2004122237 | A1 | 20040624 | US 2003-675927 | 20030929 |
| US 2004087626 | A1 | 20040506 | US 2003-405945 | 20030331 |
| WO 2005032548 | A1 | 20050414 | WO 2004-US32161 | 20040929 |
| W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | |
| RW: | BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | |

PRIORITY APPLN. INFO.: US 2002-369066P P 20020329
US 2003-405945 A2 20030331
US 2003-675927 A 20030929

OTHER SOURCE(S): MARPAT 141:71544



I



II

AB The title compds. I [wherein X1, X2 = N, NR4, O, S (with provisos); Y = O, S; A1 = (un)substituted alkyl, (hetero)cycloalkyl(alkyl), (hetero)aryl(alkyl), etc.; A2 = (un)substituted heteroaryl; R1 = O, H; R2 = NR5R6, OH; or CR1R2 = (un)substituted heterocycloalkyl, heteroaryl; R3 = H, halo, alkyl, alkoxy; R4 = H, OH, (di)alkylamino, alkyl; R5, R6 = H, (un)substituted (cyclo)alkyl, alkoxyalkyl, aminoalkyl, amidoalkyl, acyl, heterocyclyl, (hetero)aryl, etc.; or R5 and R6 are taken together to form (un)substituted heterocyclyl or heteroaryl; R7 = alkyl; and pharmaceutically acceptable salts, esters, or prodrugs] were prepared as Raf kinase inhibitors. Examples include synthetic methods and phys. data for 1400 compds., as well as descriptions of two Raf kinase bioassays. For instance, 4-amino-3-nitrophenol and (4-chloropyridin-2-yl)-N-methylcarboxamide were coupled using potassium bis(trimethylsilyl)amide and K2CO3 in DMF to give 4-[(4-amino-3-nitrophenyl)oxy]-N-methylpyridine-2-carboxamide. Pd-catalyzed hydrogenation, followed by cyclization with 4-chloro-3-(trifluoromethyl)benzeneisothiocyanate in the presence of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide•HCl in THF provided the benzimidazole II. One thousand ninety-four compds. inhibited Raf kinase activity with IC50 < 5 μ M in a Raf/Mek filtration assay or a biotinylated Raf screen. Thus, I and their pharmaceutical compns., which may comprise at least one addnl. agent, are useful for the treatment of Raf kinase mediated disorders, such as cancer (no data).

L1 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2003:796477 CAPLUS

DOCUMENT NUMBER: 139:307759

TITLE: Preparation of substituted benzazoles as Raf kinase inhibitors

INVENTOR(S): Renhowe, Paul A.; Ramurthy, Savithri; Amiri, Payman; Levine, Barry Haskell; Poon, Daniel J.; Subramanian, Sharadha; Sung, Leonard; Fantl, Wendy

PATENT ASSIGNEE(S): Chiron Corporation, USA

SOURCE: PCT Int. Appl., 259 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English



FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------------|------|-------|-----------------|-------|
| ----- | ---- | ----- | ----- | ----- |

| | | | | |
|------------------------|--|----------|-----------------|------------|
| WO 2003082272 | A1 | 20031009 | WO 2003-US10117 | 20030331 |
| W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | |
| RW: | GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | |
| CA 2480638 | AA | 20031009 | CA 2003-2480638 | 20030331 |
| EP 1499311 | A1 | 20050126 | EP 2003-745683 | 20030331 |
| R: | AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK | | | |
| BR 2003008854 | A | 20050222 | BR 2003-8854 | 20030331 |
| JP 2005529089 | T2 | 20050929 | JP 2003-579810 | 20030331 |
| PRIORITY APPLN. INFO.: | | | US 2002-369066P | P 20020329 |
| | | | WO 2003-US10117 | W 20030331 |

OTHER SOURCE(S): MARPAT 139:307759
GI



AB The title compds. [I; X1, X2 = N, NR4, O, S (with the provisos); Y = O, S; A1 = (un)substituted alkyl, cycloalkyl, aryl, etc.; A2 = (un)substituted heteroaryl; R1 = O, H, and R2 = NR5R6, OH; or CR1R2 = (un)substituted heterocycloalkyl, heteroaryl; R3 = H, halo, alkyl, alkoxy; R4 = H, OH, (di)alkylamino, alkyl; R5, R6 = H, (un)substituted alkyl, alkoxyalkyl, etc.; or R5 and R6 are taken together to form (un)substituted heterocyclyl or heteroaryl], useful for inhibition of Raf kinase activity in a human or animal subject, were prepared E.g., a 3-step synthesis of the benzimidazole II (starting from 4-amino-3-nitrophenol and (4-chloropyridin-2-yl)-N-methylcarboxamide), was given. The compds. of examples 1-1094 showed a Raf kinase inhibitory activity at an IC50 of less than 5 μ M. A composition comprising the compound I is claimed. The new compds. compns. may be used either alone or in combination with at least one addnl. agent for the treatment of a Raf kinase mediated disorder, such as cancer.

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> s 611216-21-8/rn
2 611216-21-8
0 611216-21-8D
L2 2 611216-21-8/RN
(611216-21-8 (NOTL) 611216-21-8D)

=> s 611213-97-9/rn
2 611213-97-9
0 611213-97-9D
L3 2 611213-97-9/RN
(611213-97-9 (NOTL) 611213-97-9D)

=> s 611213-23-1/rn
2 611213-23-1
0 611213-23-1D
L4 2 611213-23-1/RN
(611213-23-1 (NOTL) 611213-23-1D)

=> e amiri/au
E1 6 AMIRHOR PARVIZ/AU
E2 3 AMIRHUSIN BAHAGIAWATI/AU
E3 0 --> AMIRI/AU
E4 16 AMIRI A/AU
E5 1 AMIRI A KARIM/AU
E6 1 AMIRI ABDUL/AU
E7 1 AMIRI ABDULLAH MOHAMMED/AU
E8 2 AMIRI AFSANEH/AU
E9 4 AMIRI AHMAD/AU
E10 2 AMIRI ALI ASGHAR/AU
E11 3 AMIRI ALI S/AU
E12 1 AMIRI ALI SAFARZADEH/AU

=> e payman/au
E1 7 PAYMAL JEAN/AU
E2 1 PAYMAL JEAN ANDRE/AU
E3 0 --> PAYMAN/AU
E4 1 PAYMAN FRANK L/AU
E5 1 PAYMAN GARY H/AU
E6 21 PAYMAN J B/AU
E7 2 PAYMAN JOSEPH/AU
E8 9 PAYMAN JOSEPH B/AU
E9 1 PAYMAN L C/AU
E10 2 PAYMAN LAURENCE C/AU
E11 2 PAYMAN P W/AU
E12 1 PAYMAN S/AU

=> e renhowe/au
E1 5 RENHORN INGMAR/AU
E2 1 RENHORN INGMAR G E/AU
E3 0 --> RENHOWE/AU
E4 2 RENHOWE PAUL/AU
E5 25 RENHOWE PAUL A/AU
E6 1 RENHOWE PAUL ALLAN/AU
E7 1 RENHUA CHEN/AU
E8 1 RENHUA HUANG/AU
E9 1 RENHUA LAN/AU
E10 1 RENHUA WANG/AU
E11 1 RENHUA YANG/AU
E12 1 RENHUN LI/AU

=> s e4 or e5 or e6
2 "RENHOWE PAUL"/AU
25 "RENHOWE PAUL A"/AU

L5 1 "RENHOWE PAUL ALLAN"/AU
28 "RENHOWE PAUL"/AU OR "RENHOWE PAUL A"/AU OR "RENHOWE PAUL ALLAN"/AU

=> dup rem L5

PROCESSING COMPLETED FOR L5

L6 28 DUP REM L5 (0 DUPLICATES REMOVED)

=> s L5 and (PY<2002 or pry<2002 or AY<2002)

21804119 PY<2002
3580839 PRY<2002
3650665 AY<2002

L7 19 L5 AND (PY<2002 OR PRY<2002 OR AY<2002)

=> d 1-19 ibib abs

L7 ANSWER 1 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2003:98039 CAPLUS

DOCUMENT NUMBER: 138:153534

TITLE: Preparation of benzimidazolyl-substituted quinolinone derivatives and analogs, with inhibitory action against vascular endothelial growth factor receptor tyrosine kinase, and useful as anticancer agents

INVENTOR(S): Renhowe, Paul A.; Pecchi, Sabina; Machajewski, Timothy D.; Shafer, Cynthia M.; Taylor, Clarke; McCrea, William R.; McBride, Christopher; Jazan, Elisa

PATENT ASSIGNEE(S): Chiron Corporation, USA

SOURCE: U.S. Pat. Appl. Publ., 69 pp., Cont.-in-part of U.S. Pat. Appl. 2002 107,392.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-----------------|--------------|
| US 2003028018 | A1 | 20030206 | US 2002-116117 | 20020405 <-- |
| US 2002107392 | A1 | 20020808 | US 2001-951265 | 20010911 <-- |
| US 6605617 | B2 | 20030812 | | |
| US 2003158224 | A1 | 20030821 | US 2002-284017 | 20021030 <-- |
| US 6774237 | B2 | 20040810 | | |
| US 2004006101 | A1 | 20040108 | US 2003-387355 | 20030312 <-- |
| US 6762194 | B2 | 20040713 | | |
| CA 2481055 | AA | 20031023 | CA 2003-2481055 | 20030404 |
| WO 2003087095 | A1 | 20031023 | WO 2003-US10463 | 20030404 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| EP 1497287 | A1 | 20050119 | EP 2003-746614 | 20030404 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK | | | | |
| BR 2003008996 | A | 20050222 | BR 2003-8996 | 20030404 |
| JP 2005527587 | T2 | 20050915 | JP 2003-584051 | 20030404 |
| US 2004097545 | A1 | 20040520 | US 2003-613411 | 20030703 <-- |
| US 6800760 | B2 | 20041005 | | |
| US 2005054672 | A1 | 20050310 | US 2004-886950 | 20040708 <-- |

| | | | | |
|------------------------|----|----------|-----------------|-----------------|
| US 2005209456 | A1 | 20050922 | US 2005-92137 | 20050329 <-- |
| PRIORITY APPLN. INFO.: | | | US 2000-232159P | P 20000911 <-- |
| | | | US 2001-951265 | A2 20010911 <-- |
| | | | US 2002-116117 | A 20020405 |
| | | | US 2002-284017 | A1 20021030 |
| | | | WO 2003-US10463 | W 20030404 |
| | | | US 2004-886950 | A1 20040708 |


OTHER SOURCE(S): MARPAT 138:153534
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. of formulas I and II are provided [for I: Z = O, S, (un)substituted NH; Y = certain OH derivs., CHO, esters and amides of CO₂H, certain NH₂ derivs.; R₁-R₄ = H, halo, cyano, NO₂, OH or derivs., NH₂ or derivs., (un)substituted amidinyl, guanidinyl, alk(en/yn)yl, aryl, heterocyclyl, CHO, CO₂H and esters and amides; R₅-R₈ = H, halo, NO₂, OH or derivs., NH₂ or derivs., SH or derivs., cyano, etc.; R₉ = H, OH, (un)substituted alkoxy or aryloxy, NH₂ or derivs., (un)substituted alkyl or aryl, CHO, alkanoyl, aroyl; for II: A, B, D, E = C or N, with at least one being N; Y = H, OH or derivs., SH or derivs., NH₂ or derivs., cyano, various acyl groups, (un)substituted alk(en/yn)yl, aralkyl, heterocycloalkyl, aryl, etc.; R₁-R₈ = H, halo, NO₂, cyano, OH or derivs., NH₂ or derivs., acyl, SH or derivs., etc.; R₉ = H, OH, (un)substituted alkoxy, aryloxy, NH₂ or derivs., aryl, CHO, alkanoyl, aroyl]. Also provided are pharmaceutical formulations including the compds. or their pharmaceutically acceptable salts and a pharmaceutically acceptable carrier, which may be prepared by mixing the compds. or salts with a carrier and water. A disclosed method of treating a patient includes administering a pharmaceutical formulation according to the invention to a patient. Claims include tautomers of the compds., pharmaceutically acceptable salts, and pharmaceutically acceptable salts of the tautomers. I and II are inhibitors of receptor tyrosine kinases, and particularly of vascular endothelial growth factor receptor (VEGFR) tyrosine kinase. As such, they are inhibitors of angiogenesis, and thereby act as anticancer agents. Approx 270 invention compds. are listed, with detailed preps. given for about 50 compds. Several general preparatory methods are discussed in detail. For instance, cyclocondensation of Et 2-(benzimidazol-2-yl)acetate with the corresponding ortho-amino nitrile (preps. given), carried out in refluxing ClCH₂CH₂Cl in the presence of SnCl₄, gave the invention quinolinone III. Many compds. I and II had in vitro IC₅₀ values of less than 10 μ M with respect to flt-1 (VEGFR1), KDR (VEGFR2) and bFGF kinases (recombinant, expressed in Sf9 insect cells).

L7 ANSWER 2 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 2003:42265 CAPLUS
 DOCUMENT NUMBER: 138:106699
 TITLE: Preparation of (indazolyl)benzimidazoles and analogs as tyrosine and serine/threonine kinase inhibitors
 INVENTOR(S): Renhowe, Paul A.; Shafer, Cynthia M.; McBride, Chris; Silver, Joel; Pecchi, Sabina; Machajewski, Tim; Mccrea, Bill; Poon, Daniel; Thomas, Teresa
 PATENT ASSIGNEE(S): Chiron Corporation, USA
 SOURCE: PCT Int. Appl., 435 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|-------------------|-----------------|----------------|
| WO 2003004488 | A1 | 20030116 | WO 2002-US20844 | 20020702 <-- |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| US 2003207883 | A1 | 20031106 | US 2002-187967 | 20020702 <-- |
| EP 1401831 | A1 | 20040331 | EP 2002-752132 | 20020702 <-- |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK | | | | |
| JP 2004536113 | T2 | 20041202 | JP 2003-510655 | 20020702 <-- |
| PRIORITY APPLN. INFO.: | | | US 2001-302791P | P 20010703 <-- |
| | | | WO 2002-US20844 | W 20020702 |
| OTHER SOURCE(S): | | MARPAT 138:106699 | | |
| GI | | | | |



I

AB Title compds. I [wherein Z1-Z4 = C independently C or N; R1 = H, F, Cl, or Br; R2 = H, F, Cl, Br, CN, NO2, or (un)substituted CO2H, NH2, CONH2, NHCONH2, etc.; R3 = H, F, Cl, Br, or (un)substituted alkoxy; R4, R9, and R10 = H; R5 and R8 = independently H, F, Cl, or (un)substituted alkyl, alkoxy, NH2, heterocyclyl, etc.; R6 and R7 = independently H, F, Cl, Br, CF3, CO2H, or (un)substituted alkyl, (heterocyclyl)alkoxy, arylalkoxy, alkoxyalkoxy, (heterocyclyl)heterocyclyl, arylheterocyclyl, heterocycliloxy, aryloxy, NH2, CONH2, etc.; or R5 is absent if Z1 = N; or R6 is absent if Z2 = N; or R7 is absent if Z3 = N; or R8 is absent if Z4 = N; with the proviso that at least one of R1, R2, R3, R5, R6, R7, or R8 ≠ H; and tautomers and pharmaceutically acceptable salts thereof] were prepared as tyrosine and serine/threonine kinase inhibitors. For example, dimerization of indazole-3-carboxylic acid with PO3 followed by addition of 1,2-phenylenediamine in toluene gave 3-(1H-benzimidazol-2-yl)-1H-indazole. Seven hundred twenty-eight exemplary compds. were assays for serine/threonine kinase activity in vitro, and the majority displayed an IC50 value of less than 10 μM with respect to VEGFR1, Flk-1, bFGF, Tie-2, CHK-1, cdc2, GSK-3, NEK-2, and PDGF.

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 3 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 2002:220574 CAPLUS

DOCUMENT NUMBER: 136:263158
 TITLE: Benzimidazolyl-substituted quinolinone derivatives and analogs, with inhibitory action against vascular endothelial growth factor receptor tyrosine kinase, and useful as anticancer agents
 INVENTOR(S): Renhowe, Paul; Pecchi, Sabina; Machajewski, Tim; Shafer, Cynthia; Taylor, Clarke; McCrea, Bill; McBride, Chris; Jazan, Elisa; Wernette-Hammond, Mary-Ellen; Harris, Alex
 PATENT ASSIGNEE(S): Chiron Corporation, USA
 SOURCE: PCT Int. Appl., 207 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-----------------|-----------------|
| WO 2002022598 | A1 | 20020321 | WO 2001-US42131 | 20010911 <-- |
| WO 2002022598 | C1 | 20021121 | | |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| CA 2421120 | AA | 20020321 | CA 2001-2421120 | 20010911 <-- |
| AU 2001093275 | A5 | 20020326 | AU 2001-93275 | 20010911 <-- |
| EP 1317442 | A1 | 20030611 | EP 2001-973722 | 20010911 <-- |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR | | | | |
| BR 2001013757 | A | 20040302 | BR 2001-13757 | 20010911 <-- |
| JP 2004509112 | T2 | 20040325 | JP 2002-526851 | 20010911 <-- |
| NZ 524717 | A | 20040924 | NZ 2001-524717 | 20010911 <-- |
| ZA 2003001578 | A | 20040826 | ZA 2003-1578 | 20030226 <-- |
| NO 2003001097 | A | 20030325 | NO 2003-1097 | 20030310 <-- |
| US 2004006101 | A1 | 20040108 | US 2003-387355 | 20030312 <-- |
| US 6762194 | B2 | 20040713 | | |
| BG 107709 | A | 20040130 | BG 2003-107709 | 20030408 <-- |
| US 2005054672 | A1 | 20050310 | US 2004-886950 | 20040708 <-- |
| US 2005209456 | A1 | 20050922 | US 2005-92137 | 20050329 <-- |
| PRIORITY APPLN. INFO.: | | | | |
| | | | US 2000-232159P | P 20000911 <-- |
| | | | US 2001-951265 | A1 20010911 <-- |
| | | | WO 2001-US42131 | W 20010911 <-- |
| | | | US 2002-284017 | A1 20021030 |
| | | | US 2004-886950 | A1 20040708 |
| OTHER SOURCE(S): MARPAT 136:263158 | | | | |
| GI | | | | |

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. of formulas I and II are provided [for I: Z = O, S, (un)substituted NH; Y = certain OH derivs., CHO, esters and amides of CO₂H, certain NH₂ derivs.; R₁-R₄ = H, halo, cyano, NO₂, OH or derivs., NH₂ or derivs., (un)substituted amidinyl, guanidinyl, alk(en/yn)yl, aryl, heterocyclyl, CHO, CO₂H and esters and amides; R₅-R₈ = H, halo, NO₂, OH or derivs., NH₂ or derivs., SH or derivs., cyano, etc.; R₉ = H, OH, (un)substituted alkoxy or aryloxy, NH₂ or derivs., (un)substituted alkyl

or aryl, CHO, alkanoyl, aroyl; for II: A, B, D, E = C or N, with at least one being N; Y = H, OH or derivs., SH or derivs., NH₂ or derivs., cyano, various acyl groups, (un)substituted alk(en/yn)yl, aralkyl, heterocycloalkyl, aryl, etc.; R₁-R₈ = H, halo, NO₂, cyano, OH or derivs., NH₂ or derivs., acyl, SH or derivs., etc.; R₉ = H, OH, (un)substituted alkoxy, aryloxy, NH₂ or derivs., aryl, CHO, alkanoyl, aroyl]. Also provided are pharmaceutical formulations including the compds. or their pharmaceutically acceptable salts and a pharmaceutically acceptable carrier, which may be prepared by mixing the compds. or salts with a carrier and water. A disclosed method of treating a patient includes administering a pharmaceutical formulation according to the invention to a patient. Claims include tautomers of the compds., pharmaceutically acceptable salts, and pharmaceutically acceptable salts of the tautomers. I and II are inhibitors of receptor tyrosine kinases, and particularly of vascular endothelial growth factor receptor (VEGFR) tyrosine kinase. As such, they are inhibitors of angiogenesis, and thereby act as anticancer agents. Approx 270 invention compds. are listed, with detailed preps. given for about 50 compds. Several general preparatory methods are discussed in detail. For instance, cyclocondensation of Et 2-(benzimidazol-2-yl)acetate with the corresponding ortho-amino nitrile (preps. given), carried out in refluxing ClCH₂CH₂Cl in the presence of SnCl₄, gave the invention quinolinone III. Many compds. I and II had in vitro IC₅₀ values of less than 10 μM with respect to flt-1 (VEGFR1), KDR (VEGFR2) and bFGF kinases (recombinant, expressed in Sf9 insect cells).

REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2002:171899 CAPLUS

DOCUMENT NUMBER: 136:232301

TITLE: Preparation of heterocyclic compounds as vascular endothelial growth factor receptor tyrosine kinase inhibitors

INVENTOR(S): Renhowe, Paul; Machajewski, Tim; Shafer, Cynthia; Wernette-Hammond, Mary-ellen; Harris, Alex

PATENT ASSIGNEE(S): Chiron Corporation, USA; Pecci Sabina

SOURCE: PCT Int. Appl., 115 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---------------|--|----------|-----------------|--------------|
| WO 2002018383 | A2 | 20020307 | WO 2001-US41942 | 20010830 <-- |
| WO 2002018383 | A3 | 20020829 | | |
| W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | |
| RW: | GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | |
| AU 2001093233 | A5 | 20020313 | AU 2001-93233 | 20010830 <-- |
| US 2002103230 | A1 | 20020801 | US 2001-943382 | 20010830 <-- |
| US 6756383 | B2 | 20040629 | | |
| EP 1313734 | A2 | 20030528 | EP 2001-973678 | 20010830 <-- |
| R: | AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR | | | |
| JP 2004507543 | T2 | 20040311 | JP 2002-523898 | 20010830 <-- |
| US 2004002518 | A1 | 20040101 | US 2003-452786 | 20030602 <-- |

US 6759417
US 2005137188
PRIORITY APPLN. INFO.:


B2 20040706
A1 20050623

US 2004-823995
US 2000-231829P
US 2001-943382
WO 2001-US41942
US 2003-452786
20040414 <--
P 20000901 <--
A3 20010830 <--
W 20010830 <--
A1 20030602

OTHER SOURCE(S):
GI
MARPAT 136:232301



I



II

AB Heterocyclic compds. of formula I [Y = OH, SH, NH2, CN, acyl, etc.; Z = O, S, NH; R1R2 = 5-7 membered ring comprising at least one O, N or S atom; R3 = H, OH, alkoxy, NH2, alkyl, etc.; R4-R7 = H, Cl, Br, F, I, NO2, CN, OH, acyl, etc.] are prepared. The compds. are inhibitors of vascular endothelial growth factor receptor tyrosine kinase. Thus, II was prepared from 3-aminopyridine-4-carboxylic acid, Me 2-(chlorocarbonyl)acetate and 1,2-phenylenediamine. The prepared compds. displayed an IC50 value of less than 10 μ M against various protein tyrosine kinases.

L7 ANSWER 5 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2002:171845 CAPLUS

DOCUMENT NUMBER: 136:232121

TITLE: Preparation of guanidinobenzamides as melanocortin-4 receptor agonists useful for treating diseases such as obesity and type II diabetes

INVENTOR(S): Renhowe, Paul A.; Chu, Daniel; Boyce, Rustum; Ni, Zhi-jie; Duhl, David; Tozzo, Effie; Johnson, Kirk; Myles, David

PATENT ASSIGNEE(S): Chiron Corporation, USA

SOURCE: PCT Int. Appl., 145 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent



LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---------------|--|----------|-----------------|--------------|
| WO 2002018327 | A2 | 20020307 | WO 2001-US27206 | 20010831 <-- |
| WO 2002018327 | A3 | 20020808 | | |
| W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | |
| RW: | GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | |
| CA 2420694 | AA | 20020307 | CA 2001-2420694 | 20010831 <-- |
| AU 2001088604 | A5 | 20020313 | AU 2001-88604 | 20010831 <-- |

| | | | | |
|---|----|-------------------|-----------------|-----------------|
| US 2002137939 | A1 | 20020926 | US 2001-945384 | 20010831 <-- |
| US 6638927 | B2 | 20031028 | | |
| SI 21267 | C | 20040229 | SI 2001-20058 | 20010831 <-- |
| BR 2001013643 | A | 20040302 | BR 2001-13643 | 20010831 <-- |
| JP 2004508304 | T2 | 20040318 | JP 2002-523445 | 20010831 <-- |
| EP 1409468 | A2 | 20040421 | EP 2001-968352 | 20010831 <-- |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR | | | | |
| NZ 524897 | A | 20040827 | NZ 2001-524897 | 20010831 <-- |
| ZA 2003001544 | A | 20040622 | ZA 2003-1544 | 20030225 <-- |
| NO 2003000929 | A | 20030430 | NO 2003-929 | 20030227 <-- |
| US 2003199499 | A1 | 20031023 | US 2003-379397 | 20030304 <-- |
| BG 107639 | A | 20031128 | BG 2003-107639 | 20030318 <-- |
| PRIORITY APPLN. INFO.: | | | US 2000-230565P | P 20000831 <-- |
| | | | US 2000-245579P | P 20001106 <-- |
| | | | US 2001-945384 | A3 20010831 <-- |
| | | | WO 2001-US27206 | W 20010831 <-- |
| OTHER SOURCE(S): | | MARPAT 136:232121 | | |
| GI | | | | |



AB Compds. I and II, e.g. [4-(((1Z)-2-aza-2-cyclopentyl-1-piperazinylvinyl)amino)phenyl]-N-[2-(2,4-dichlorophenyl)ethyl]carboxamide, are new where the variables R1 through R10 have the values set forth below. Such compds. and prodrugs thereof, pharmaceutically acceptable salts thereof, stereoisomers thereof, tautomers thereof, hydrates thereof, hydrides thereof, or solvates thereof, have use in treating diseases such as obesity and type II diabetes, and may be provided as pharmaceutical formulations in conjunction with a pharmaceutically acceptable carrier. In I and II, R1 is H, and substituted and unsubstituted arylalkyl, heteroarylalkyl, aryl, heteroaryl, heterocyclyl, cycloalkyl, heterocyclylalkyl, cycloalkylalkyl, alkenyl, alkynyl, and alkyl groups; R2 is substituted and unsubstituted arylalkyl, heteroarylalkyl, aryl, heteroaryl, heterocyclyl, cycloalkyl, heterocyclylalkyl, cycloalkylalkyl, alkenyl, alkynyl, and alkyl groups; R3 is substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, heteroaryl, heterocyclyl, heterocyclylalkyl, arylalkyl, heteroarylalkyl, and cycloalkylalkyl groups. R4 is H, and substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, arylalkyl, heteroarylalkyl, and cycloalkylalkyl groups; R5 is substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, arylalkyl, heteroarylalkyl, and cycloalkylalkyl groups; or R4 and R5, together with

the N to which they are bound, form a substituted or unsubstituted heterocyclyl or heteroaryl group; R6, R7, R8, and R9 may be the same or different, and are each independently H, Cl, I, F, Br, OH, NH₂, CN, NO₂, and substituted and unsubstituted alkoxy, amino, alkyl, alkenyl, alkynyl, alkylamino, dialkylamino, cycloalkyl, heterocyclylamino, heteroarylamino, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, cycloalkylaminocarbonyl, arylaminocarbonyl, heterocyclylaminocarbonyl, and heteroarylaminocarbonyl groups; R10 is H, and substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkylalkyl, aryl, and arylalkyl groups. Although the methods of preparation are not claimed, .apprx.60 example preps., involving resin- and non-resin-based methods, are included. EC50 values of test compds. were determined by treating cells expressing MC4-R with test compound and lyzing the cells and measuring intercellular cAMP concentration with Amersham-Pharmacia RPA-559 cAMP Scintillation Proximity Assay (SPA) kit. Compds. listed displayed -log EC50 values .gtorsim.3. In vivo studies were conducted using mice to observe the effect of MC4-R agonists on energy intake, body weight, hyperinsulinemia, and glucose levels; results are given for 4-[(N-cyclohexyl-3,5-dimethylpiperazine-1-carboximidoyl)amino]-N-[2-(2,4-dichlorophenyl)ethyl]benzamide.

L7 ANSWER 6 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2001:674646 CAPLUS
DOCUMENT NUMBER: 135:313056
TITLE: Growth factor receptor kinases in cancer
AUTHOR(S): Renhowe, Paul A.
CORPORATE SOURCE: Chiron Corporation, Emeryville, CA, 94608-2916, USA
SOURCE: Annual Reports in Medicinal Chemistry (2001), 36, 109-118
CODEN: ARMCBI; ISSN: 0065-7743
PUBLISHER: Academic Press
DOCUMENT TYPE: Journal; General Review
LANGUAGE: English

AB A review, with 93 refs., focuses on the ATP-competitive inhibitors of the growth factor-receptor tyrosine kinases. Topics discussed include epidermal, platelet-derived, fibroblast, and vascular endothelial growth factor receptor tyrosine kinase inhibitors. The number of kinases expressed throughout the body will make it difficult to determine the inhibitory profile of any compound designed to inhibit specific members of this class of enzymes. (c) 2001 Academic Press.

REFERENCE COUNT: 93 THERE ARE 93 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 7 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2000:293395 CAPLUS
DOCUMENT NUMBER: 133:43696
TITLE: A Practical Entry to the Crambescidin Family of Guanidine Alkaloids. Enantioselective Total Syntheses of Ptilomycalin A, Crambescidin 657 and Its Methyl Ester (Neofolitispates 2), and Crambescidin 800
AUTHOR(S): Coffey, D. Scott; McDonald, Andrew I.; Overman, Larry E.; Rabinowitz, Michael H.; Renhowe, Paul A.
CORPORATE SOURCE: Department of Chemistry, University of California, Irvine, CA, 92697-2025, USA
SOURCE: Journal of the American Chemical Society (2000), 122(20), 4893-4903
CODEN: JACSAT; ISSN: 0002-7863
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 133:43696

AB Among the most structurally remarkable guanidine natural products are the crambescidin/ptilomycalin A family of marine alkaloids. The evolution of a practical strategy for preparing pharmacol. significant crambescidin/ptilomycalin A alkaloids that lack oxidation at C13 is

described. The first total syntheses of crambescidin 800 (2), crambescidin 657 (6), and neofolitispatate 2 (7) are reported in full detail. The central strategic step in these convergent total syntheses is tethered Biginelli condensation of a β -keto ester with an ureido aminal to combine all carbons of the guanidine nucleus and set the pivotal C10-C13 stereo-relationship. The total synthesis of crambescidin 800 was accomplished in 3% overall yield from com. available 3-butyn-1-ol by way of 16 isolated and purified intermediates. Full details of our earlier total synthesis of ptilomycalin A (1) are also presented. The total syntheses described in this disclosure confirm the stereochem. assignments of 1, 2, 6, and 7 and rigorously establish that the absolute configuration of the hydroxyspermidine side chain of crambescidin 800 is S.

REFERENCE COUNT: 77 THERE ARE 77 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1999:812696 CAPLUS
DOCUMENT NUMBER: 132:92807
TITLE: Advances in solid-supported organic synthesis methods, 1998 to 1999
AUTHOR(S): Nuss, John M.; Renhowe, Paul A.
CORPORATE SOURCE: Chiron Corporation, Emeryville, CA, 94608, USA
SOURCE: Current Opinion in Drug Discovery & Development (1999), 2(6), 631-650
CODEN: CODDF; ISSN: 1367-6733
PUBLISHER: Current Drugs Ltd.
DOCUMENT TYPE: Journal; General Review
LANGUAGE: English

AB A review with 69 refs. is given. Combinatorial chemical is now regarded as an important component of the drug discovery process and is increasingly having an impact in other areas of the chemical sciences, such as catalysis and materials science. Solid-supported organic synthesis continues to be an integral component in the efficient assembly of combinatorial libraries. This review attempts to describe some of the most important recent developments in solid-supported organic synthesis during the period 1998 to 1999. Particular emphasis is placed on the development of novel, efficient methods for the synthesis of diverse, non-oligomeric libraries and structurally complex mols.


REFERENCE COUNT: 66 THERE ARE 66 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1999:811233 CAPLUS
DOCUMENT NUMBER: 132:64265
TITLE: Preparation of aminopyrimidines and -pyridines as glycogen synthase kinase 3 inhibitors
INVENTOR(S): Nuss, John M.; Harrison, Stephen D.; Ring, David B.; Boyce, Rustum S.; Brown, Sean P.; Goff, Dane; Johnson, Kirk; Pfister, Keith B.; Ramurthy, Savithry; Renhowe, Paul A.; Seely, Lynn; Subramanian, Sharadha; Wagman, Allan S.; Zhou, Xiaohui A.
PATENT ASSIGNEE(S): Chiron Corporation, USA
SOURCE: PCT Int. Appl., 262 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|--|------|----------|-----------------|--------------|
| WO 9965897 | A1 | 19991223 | WO 1999-US13809 | 19990618 <-- |
| W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, | | | | |

MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ,
 TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ,
 MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK,
 ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG,
 CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
 AU 9949566 A1 20000105 AU 1999-49566 19990618 <--
 EP 1087963 A1 20010404 EP 1999-933522 19990618 <--
 EP 1087963 B1 20040825
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO
 US 6489344 B1 20021203 US 1999-336098 19990618 <--
 JP 2003527303 T2 20030916 JP 2000-554722 19990618 <--
 AT 274510 E 20040915 AT 1999-933522 19990618 <--
 US 2003130289 A1 20030710 US 2002-309535 20021203 <--
 PRIORITY APPLN. INFO.: US 1998-89978P P 19980619 <--
 US 1999-336098 A3 19990618 <--
 WO 1999-US13809 W 19990618 <--
 OTHER SOURCE(S): MARPAT 132:64265
 GI



AB RZCR2R12CR3R13Z1R5 [I; R = (un)substituted (hetero)aryl; Z = O, NR1, CR1R11; Z1 = O, NR4, CR4R14; R1-R4 = H, OH, NH2, alkyl, alkoxy, etc.; R5 = (un)substituted 2-pyridyl or -pyrimidyl; R11-R14 = H or alkyl] were prepared. Thus, 2-chloro-5-nitropyridine was aminated by H2N(CH2)3NH2 and the product N-acylated by benzotriazolecarboxamidinium tosylate to give the alkylguanidine which was cyclocondensed with resin-bound 4-(MeCO)C6H4CONHCH2C6H4Br-3 and Cs2CO3 to give, after resin cleavage, title compound II. Data for biol. activity of I were given.


REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 10 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 1999:499760 CAPLUS
 DOCUMENT NUMBER: 131:257831
 TITLE: Investigations of a Nucleophilic Alaninol Synthon
 Derived from Serine
 AUTHOR(S): Sibi, Mukund P.; Rutherford, Drew; Renhowe, Paul
 A.; Li, Biqin
 CORPORATE SOURCE: Department of Chemistry, North Dakota State
 University, Fargo, ND, 58105-5516, USA
 SOURCE: Journal of the American Chemical Society (1999
), 121(33), 7509-7516
 CODEN: JACSAT; ISSN: 0002-7863
 PUBLISHER: American Chemical Society
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 131:257831
 AB A nucleophilic synthon, (S)-(+)-4-(2-oxazolidonyl)-
 methyltriphenylphosphinyl iodide, available from L-serine in five steps

(overall yield of 52%), reacts with aldehydes to produce alkenes in good to excellent yields (74-89%) and, in some cases, provides excellent stereocontrol of the new double bond. The geometry of the newly formed double bond is influenced by the nature of the aldehyde and reaction conditions. The trends in olefin configuration are discussed. Application of this methodol. allows for easy preparation of mols. containing double bonds allylic to nitrogen, including oxazolidinones and β,γ -unsatd. amino alcs. Several of the unsatd. oxazolidinones are converted to β,γ -unsatd. amino alcs. in high yields (75 to 90%).

REFERENCE COUNT: 94 THERE ARE 94 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 11 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 1997:226492 CAPLUS
 DOCUMENT NUMBER: 126:199384
 TITLE: Total Synthesis of (+)-Isolaurepinnacin. Use of Acetal-Alkene Cyclizations To Prepare Highly Functionalized Seven-Membered Cyclic Ethers
 AUTHOR(S): Berger, Daniel; Overman, Larry E.; Renhowe, Paul A.
 CORPORATE SOURCE: Department of Chemistry, University of California, Irvine, CA, 92697-2025, USA
 SOURCE: Journal of the American Chemical Society (1997), 119(10), 2446-2452
 CODEN: JACSAT; ISSN: 0002-7863
 PUBLISHER: American Chemical Society
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 GI



AB The first synthesis of title compound I [R = CH₂CH:CHC.tplbond.CH-(E)] is described. The synthesis features an acetal-vinylsilane cyclization to stereoselectively form the cis-2,7-disubstituted oxepene ring and introduce Δ^4 -unsatn. Starting with (2R,3S)-2,3-epoxypentan-1-ol, mixed acetal II is formed in five steps and 72% overall yield. Treatment of II with excess BCl₃ in CH₂Cl₂ at -78 \rightarrow 0 $^{\circ}$ C promotes cyclization to afford Δ^4 -oxepene I (R = CH₂CH₂CH₂OH) in 90% yield after deprotection of the silyl ether. Elaboration of the (E)-enyne functionality of the six-carbon side chain completes the synthesis of (+)-isolaurepinnacin.



REFERENCE COUNT: 51 THERE ARE 51 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 12 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 1997:218872 CAPLUS
 DOCUMENT NUMBER: 126:293272
 TITLE: Developing a general strategy for the solid supported synthesis of heterocycles: applications to the generation of molecular diversity and drug discovery
 AUTHOR(S): Nuss, John M.; Desai, Manoj C.; Zuckermann, Ronald N.;

Singh, Rajinder; **Renhowe, Paul A.**; Goff, Dane A.; Chinn, Jason P.; Wang, Liang; Dorr, Hilary; Brown, Edward G.; Subramanian, Sharadha
CORPORATE SOURCE: Chiron Corp., Emeryville, CA, 94608, USA
SOURCE: Pure and Applied Chemistry (1997), 69(3), 447-452
CODEN: PACHAS; ISSN: 0033-4545
PUBLISHER: Blackwell
DOCUMENT TYPE: Journal; General Review
LANGUAGE: English
AB The development of a general strategy for the generation of mol. diversity in the form of novel, non-amide based heterocyclic structures is described with 19 refs. The generation of diverse peptide and peptidomimetic libraries, the automation of these strategies and computational approaches to diversity generation are also discussed. The main focus of this lecture is the progression of these concepts into a strategy for small mol. library generation, and hence the generation of small mol. therapeutic leads.
REFERENCE COUNT: 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 13 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1997:141020 CAPLUS
DOCUMENT NUMBER: 126:157521
TITLE: Combinatorial libraries of substrate-bound cyclic organic compounds
INVENTOR(S): Desai, Manoi C.; Nuss, John M.; Spear, Kerry L.; Singh, Rajinder; **Renhowe, Paul A.**; Brown, Edward G.; Richter, Lutz; Scott, Barbara O.
PATENT ASSIGNEE(S): Chiron Corporation, USA
SOURCE: PCT Int. Appl., 100 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|-------------------|-----------------|----------------|
| WO 9640201 | A1 | 19961219 | WO 1996-US7684 | 19960523 <-- |
| W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI | | | | |
| RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML | | | | |
| US 5958792 | A | 19990928 | US 1995-485006 | 19950607 <-- |
| CA 2221508 | AA | 19961219 | CA 1996-2221508 | 19960523 <-- |
| AU 9659320 | A1 | 19961230 | AU 1996-59320 | 19960523 <-- |
| EP 777492 | A1 | 19970611 | EP 1996-916633 | 19960523 <-- |
| EP 777492 | B1 | 20050119 | | |
| R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE | | | | |
| CN 1192154 | A | 19980902 | CN 1996-195924 | 19960523 <-- |
| JP 2001518053 | T2 | 20011009 | JP 1997-500720 | 19960523 <-- |
| AT 287417 | E | 20050215 | AT 1996-916633 | 19960523 <-- |
| PRIORITY APPLN. INFO.: | | | US 1995-485006 | A 19950607 <-- |
| | | | WO 1996-US7684 | W 19960523 <-- |
| OTHER SOURCE(S): | | MARPAT 126:157521 | | |
| GI | | | | |




AB The invention relates to libraries of cyclic organic compds. and methods of producing and assaying such libraries. According to the invention, each cyclic organic compound is constructed from a starting material in the form of a solid surface derivatized with a starting resin. Compds. are reacted with the resin to add or form a cyclic group. The reactions are preferably carried out using a split resin procedure so that different compds. can be reacted with a plurality of subamounts so as to increase the size of the library. For example, compds. are reacted with a solid support bound starting resin to obtain a compound which includes an aldehyde functional group wherein the aldehyde compound or compds. reacted with it have substituents which are varied such that a mixture of products is obtained. The invention further relates to methods of producing combinatorial libraries of cyclic organic compds. from substrate bound compds. by cleaving the compds. from the support after synthesizing is completed and to assaying libraries of such compds. Several actual examples show the construction of aromatic and heterocyclic organic compds. on Rink amide resins. Addnl. prophetic examples show the preparation of libraries by analogous methods. For instance, the Rink amide resin-bound aldehyde Resin-NHCOC6H4CHO-4 was cyclized with sarcosine and di-Me muconate at 110°, and the product was worked up and cleaved from the support with CF3CO2H in CH2Cl2, to give a total of 4 isomers of the target compds. I and II.

L7 ANSWER 14 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 1995:852174 CAPLUS
 DOCUMENT NUMBER: 123:286366
 TITLE: Enantioselective total synthesis of
 (+)-isolaurepinnacin and enantioselective total
 synthesis of (-)-ptilomycalin a
 AUTHOR(S): Renhowe, Paul Allan
 CORPORATE SOURCE: Univ. of California, Irvine, CA, USA
 SOURCE: (1995) 148 pp. Avail.: Univ. Microfilms
 Int., Order No. DA9525158
 From: Diss. Abstr. Int., B 1995, 56(3), 1429
 DOCUMENT TYPE: Dissertation
 LANGUAGE: English
 AB Unavailable

L7 ANSWER 15 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 1995:397708 CAPLUS
 DOCUMENT NUMBER: 122:291250
 TITLE: Enantioselective Total Synthesis of (-)-Ptilomycalin A
 AUTHOR(S): Overman, Larry E.; Rabinowitz, Michael H.;

CORPORATE SOURCE: **Renhowe, Paul A.**
 Department of Chemistry, University of California,
 Irvine, CA, 92717-2025, USA
 SOURCE: **Journal of the American Chemical Society (1995**
), 117(9), 2657-8
 CODEN: JACSAT; ISSN: 0002-7863
 PUBLISHER: American Chemical Society
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 122:291250
 GI



I



AB The total synthesis of the title compound (I) was accomplished in a
 convergent from three readily available enantioenriched secondary alcs.

L7 ANSWER 16 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 1994:508932 CAPLUS
 DOCUMENT NUMBER: 121:108932
 TITLE: Regioselective Opening of Terminal Epoxides with
 2-(Trialkylsilyl)allyl Organometallic Reagents
 AUTHOR(S): Overman, Larry E.; **Renhowe, Paul A.**
 CORPORATE SOURCE: Department of Chemistry, University of California,
 Irvine, CA, 92717-2025, USA
 SOURCE: **Journal of Organic Chemistry (1994), 59(15),**
 4138-42
 CODEN: JOCEAH; ISSN: 0022-3263
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 121:108932

AB Terminal epoxides react with 2-(trialkylsilyl)allyl organometallics (Sn,
 Si, Li, Cu) with varying degrees of efficiency depending upon the nature
 of the epoxide. The combination of [2-(trimethylsilyl)allyl]tributylstann
 ane and EtAlCl₂ is optimum and, in general, provides 1-substituted
 4-(trimethylsilyl)-4-penten-1-ol products, e.g.
 CH₂:C(SiMe₂Ph)CH₂CH₂CHOHBu, in good yield.


L7 ANSWER 17 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 1993:670893 CAPLUS
 DOCUMENT NUMBER: 119:270893
 TITLE: Enantioselective total synthesis of
 (+)-isolaurepinnacin
 AUTHOR(S): Berger, Daniel; Overman, Larry E.; **Renhowe, Paul**

CORPORATE SOURCE: A.
Dep. Chem., Univ. California, Irvine, CA, 92717-2025,
USA
SOURCE: Journal of the American Chemical Society (1993
, 115(20), 9305-6
CODEN: JACSAT; ISSN: 0002-7863
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 119:270893
GI




AB The total synthesis of (+)-isolaurepinnacin (I) was accomplished in 12 total steps and 15% overall yield from cis-2-penten-1-ol. This total synthesis rigorously establishes the S configuration of I at C(13), which had previously been assigned on biosynthetic grounds only, and corrects the rotation of I to be dextrorotatory. The key step is the completely stereocontrolled cyclization of the mixed acetal II to provide the cis-2,7-disubstituted-Δ⁴-oxepene in 90% yield. This conversion highlights the extraordinary selectivity that can be realized in acetal-alkene cyclizations and demonstrates that chiral α-chloro oxocarbenium ions are sufficiently configurationally stable to not epimerize during a favorable acetal-alkene cyclization.

L7 ANSWER 18 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1992:490556 CAPLUS
DOCUMENT NUMBER: 117:90556
TITLE: A novel thermolytic annulation of an oxazolidinone:
an enantiospecific synthesis of (-)-slaframycin
AUTHOR(S): Sibi, Mukund P.; Christensen, James W.; Li, Biqin;
Renhowe, Paul A.
CORPORATE SOURCE: Dep. Chem., North Dakota State Univ., Fargo, ND,
58105, USA
SOURCE: Journal of Organic Chemistry (1992), 57(16),
4329-30
CODEN: JOCEAH; ISSN: 0022-3263
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 117:90556
GI



AB The stereospecific syntheses of (-)-slaframine (I) and (-)-8a-epidesacetoxyslaframine (II) from (+)-N-BOC-3-hydroxyproline Et ester and (-)-N-BOC-proline Me ester, resp., through a thermolytic annulation of oxazolidinones III and IV, resp. illustrates an efficient general method for the formation of the β -amino piperidine structure. (-)-Slaframine was prepared in 27% overall yield from (+)-N-BOC-3-hydroxyproline Et ester, and (-)-8a-epidesacetoxyslaframine was prepared in 59% overall yield from (-)-N-BOC-proline Me ester. The yields for the key thermolytic annulations were 92% and 83% resp. The convergent method is applicable to gram scale preps., and has the potential for stereoisomer and analog preparation

L7 ANSWER 19 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 1991:143961 CAPLUS
 DOCUMENT NUMBER: 114:143961
 TITLE: A new nucleophilic alaninol synthon from serine
 AUTHOR(S): Sibi, Mukund P.; Renhowe, Paul A.
 CORPORATE SOURCE: Dep. Chem., North Dakota State Univ., Fargo, ND, 58105, USA
 SOURCE: Tetrahedron Letters (1990), 31(51), 7407-10
 CODEN: TELEAY; ISSN: 0040-4039
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 114:143961
 GI



AB A new nucleophilic alaninol synthon (I) derived from serine is reported. The utility of I in the stereoselective synthesis of β,γ -unsatd. amino alcs., e.g. II (R = Me, Ph), is described.

=> logoff
 ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF

LOGOFF? (Y)/N/HOLD:y
COST IN U.S. DOLLARS

FULL ESTIMATED COST

| SINCE FILE | TOTAL |
|------------|---------|
| ENTRY | SESSION |
| 94.51 | 95.77 |

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

CA SUBSCRIBER PRICE

| SINCE FILE | TOTAL |
|------------|---------|
| ENTRY | SESSION |
| -14.60 | -14.60 |

STN INTERNATIONAL LOGOFF AT 14:45:15 ON 25 OCT 2005